Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
  • A61K38/46—Hydrolases (3)
  • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
  • A61K38/46—Hydrolases (3)
  • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
  • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
  • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
  • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/14—Hydrolases (3)
  • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/14—Hydrolases (3)
  • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
  • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/14—Hydrolases (3)
  • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
  • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
  • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Y—ENZYMES
  • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
  • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
  • C12Y302/01096—Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (3.2.1.96)
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N33/6854—Immunoglobulins
  • G01N33/686—Anti-idiotype
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
  • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
  • C07K2317/52—Constant or Fc region; Isotype
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
  • C07K2317/54—F(ab')2
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
  • Y02P20/00—Technologies relating to chemical industry
  • Y02P20/50—Improvements relating to the production of bulk chemicals
  • Y02P20/582—Recycling of unreacted starting or intermediate materials

Definitions

• the disclosure relates to a method for improving the benefit of a therapy or a therapeutic agent to a subject.
• the method comprises (a) administering to the subject an agent which reduces Fc receptor binding of serum IgG molecules in the subject; and (b) subsequently administering said therapy or said therapeutic agent to the subject.
• the disclosure also relates to a method for reducing the effect of pathogenic autoantibodies in a subject, the method comprising (a) administering to the subject an agent which reduces Fc receptor binding of serum IgG molecules in the subject and optionally (b) subsequently subjecting the subject to a treatment which removes endogenous autoantibodies.
• the disclosure also relates to a kit for carrying out a method of the disclosure.
• Antibodies are components of the immune system, which recruit other immune system elements to particular targets within the body. Antibodies are specific to target antigens through the specificity of the Fab domains. Antibodies recruit other elements of the immune system through the interaction of the antibody fragment crystallisable (Fc) domain with Fc receptors (FcRs) expressed on the surface of immune cells.
• Fc antibody fragment crystallisable
• FcRs Fc receptors
• the predominant antibodies in mammalian serum are usually of the immunoglobulin G (IgG) class: IgG1, IgG2, IgG3 and IgG4. These antibodies bind the human FcRs: Fc ⁇ RI, R ⁇ IIa, R ⁇ IIb, RyIIIa and Fc ⁇ Rn, and the complement Fc receptor C1q.
• the efficacy of the recruitment of the cellular immune system by IgG molecules is influenced by the affinity of the Fc to the FcR(s).
• the interaction between the Fc domain of an antibody and an FcR is important both for the action of antibodies which are administered as therapeutic agents and also of antibodies which play a pathogenic role in various autoimmune conditions including antibody-mediated transplant rejection.
• WO 2006/131347 discloses uses of IdeS.
• WO 2013/110946 discloses compositions comprising an agent which reduces Fc receptor binding of endogenous serum antibodies.
• WO 2008/071418 discloses uses of EndoS.
• Johansson et al. PLoS ONE 2008 3(2): e1692 provides information concerning the IgG-cleaving activity of IdeS in vitro and in vivo.
• the present invention provides a protein having IgG cysteine protease activity for use in a method for improving the benefit to a human subject of a therapy, the method comprising (a) administering to the subject the protein having IgG cysteine protease activity; and (b) subsequently administering said therapy to the subject; wherein:
• the window of defined length may also be used to administer a therapy, such as an organ transplant, which would otherwise be ineffective due to the action of anti-donor IgG antibodies present in the serum of the patient.
• a therapy such as an organ transplant
• the method may be used to desensitize a patient prior to organ transplantation.
• the present disclosure provides a method for improving the benefit to a subject of a therapy or a therapeutic agent, the method comprising (a) administering to the subject an agent which reduces Fc receptor binding of serum IgG molecules in the subject; and (b) subsequently administering said therapy or said therapeutic agent to the subject; wherein:
• the disclosure may also be used to remove or to reduce the effect of antibodies in a subject. This may be particularly helpful in a patient suffering from an autoimmune disease which is wholly or partly mediated by pathogenic autoantibodies, such as Guillain-Barre syndrome or Goodpastures syndrome.
• pathogenic autoantibodies such as Guillain-Barre syndrome or Goodpastures syndrome.
• the disclosure also relates to a method for removing or reducing the effect of antibodies in a subject, the method comprising (a) administering to the subject an agent which reduces Fc receptor binding of serum IgG molecules in the subject, and optionally (b) subsequently subjecting the subject to a treatment which removes endogenous autoantibodies; wherein
• patient and “subject” are used interchangeably and typically refer to a human.
• an agent which reduces Fc receptor binding to serum IgG molecules means an agent which achieves this effect by any suitable mechanism.
• Various agents are known to reduce the Fc receptor interaction of IgG molecules. These agents are often proteins of bacterial origin and may act in a variety of different ways.
• such a protein may be an IgG cysteine protease which cleaves IgG such that the antigen binding domains and Fc interacting domains are separated from each other.
• IgG cysteine protease which cleaves IgG such that the antigen binding domains and Fc interacting domains are separated from each other.
• Fc receptor interaction of serum IgG molecules is reduced because the quantity of intact IgG molecules in the serum is reduced.
• such a protein may be an IgG endoglycosidase which cleaves a glycan structure on the Fc interacting domain of IgG, particularly the N-linked bi-antennary glycan at position Asn-297 (Kabat numbering).
• This glycan structure has a critical role in Fc receptor binding.
• the reduction in binding preferably results in an increase in the equilibrium binding constant for the IgG:FcyR interaction by a factor of at least two.
• the present disclosure provides a method for improving the benefit to a subject of a therapy or a therapeutic agent.
• the method comprises two steps, which are referred to herein as steps (a) and (b).
• Step (a) comprises administering to the subject an agent which reduces Fc receptor binding of serum IgG molecules in the subject.
• the amount of the agent administered is preferably sufficient to eliminate Fc receptor binding by all or substantially all IgG molecules present in the serum of the subject.
• Step (b) comprises subsequently administering to the subject the said therapy or therapeutic agent.
• Steps (a) and (b) are separated by a time interval which is preferably sufficient for Fc receptor binding by all or substantially all IgG molecules present in the serum of the subject to be eliminated.
• the said interval may typically be of at least 30 minutes and at most 21 days.
• the disclosure also provides an agent which reduces Fc receptor binding of serum IgG molecules in a subject for use in a method for improving the benefit to said subject of a therapy or a therapeutic agent, wherein the method comprises: (a) administering to the subject an amount of the agent sufficient to eliminate Fc receptor binding by all or substantially all IgG molecules present in the serum of the subject; and (b) subsequently administering said therapy or said therapeutic agent to the subject, wherein steps (a) and (b) are separated by a time interval sufficient for Fc receptor binding by substantially all IgG molecules present in the serum of the subject to be eliminated.
• the said interval may typically be of at least 30 minutes and at most 21 days.
• the disclosure also provides the use of an agent which reduces Fc receptor binding of serum IgG molecules in a subject in the manufacture of a medicament for improving the benefit to said subject of a therapy or a therapeutic agent, wherein said improving comprises: (a) administering to the subject an amount of the agent sufficient to eliminate Fc receptor binding by all or substantially all IgG molecules present in the serum of the subject; and (b) subsequently administering said therapy or said therapeutic agent to the subject, wherein steps (a) and (b) are separated by a time interval sufficient for Fc receptor binding by substantially all IgG molecules present in the serum of the subject to be eliminated.
• the said interval may typically be of at least 30 minutes and at most 21 days.
• Step (a) is conducted before step (b), and steps (a) and (b) are separated by a time interval sufficient for Fc receptor binding by all or substantially all IgG molecules present in the serum of the subject to be eliminated.
• substantially all it is typically meant that Fc receptor binding by serum IgG is reduced to less than 5% of the level that was present prior to step (a).
• the agent administered is (a) is a protease (such as IdeS)
• the interval will be the time required for the agent to cleave at least 95% of serum IgG in the subject, as measured by any suitable assay.
• the said interval may typically be of at least 30 minutes and at most 21 days.
• the lower limit of the time interval between steps (a) and (b) is determined by the time that it takes for the agent administered in step (a) to eliminate Fc receptor binding by substantially all IgG molecules present in the serum of the subject. This may optionally be determined by testing a serum sample taken from the individual and applying any suitable assay. Some exemplary suitable assays are described in the Examples.
• Such an assay may directly test for the presence of IgG molecules in a serum sample that are able to bind to one or more Fc receptors, for example in an ELISA.
• such an assay may be indirect, in that it may test for the presence of one or more reaction products that are expected to result from the treatment of IgG with the agent administered in step (a).
• the agent is an enzyme which cleaves the IgG protein
• a serum sample may be assayed for the presence of intact IgG molecules or the fragments which result from cleavage. This may be achieved by any suitable method, such as by separating the molecules and fragments based on molecular weight, e.g.
• the inventors developed a new assay for IgG concentration which is compatible with samples affected by the presence of an IgG cysteine protease (such as IdeS) and may be used in any clinical setting, including (but not limited to) uses in combination with other methods of the invention.
• IgG cysteine protease such as IdeS
• Said method is able to discriminate between intact IgG and IdeS-generated F(ab') 2 -fragments. This was accomplished by making use of antibodies that detect the different fragments i.e. an anti-Fab antibody and an anti-Fc antibody.
• the antibodies used in the assay must not be a substrate for the IgG cysteine protease affecting the sample (typically IdeS). This avoids the assay reagents being affected by any active protease which may be present in a sample. This can be accomplished by testing IgG from different species or by using antibody fragments (i.e. Fab fragments or F(ab') 2 fragments) in place of whole antibodies.
• an anti-F(ab') 2 agent is incubated with the sample as a capture reagent.
• the capture reagent is typically immobilized, for example in the wells of an assay plate. Bound IgG is then detected by incubation with an anti-Fc agent as the detector reagent. Thus, only IgG which possess both Fab and Fc parts will be detected, contrary to the nephelometry and turbidimetry methods.
• the detector reagent may typically be conjugated directly or indirectly to a moiety to facilitate detection, such as a fluorescent dye or an enzyme which reacts with a chromogenic substrate.
• the capture and detector reagents can be any other molecule that specifically recognizes the Fab- or Fc-part of IgG and can be used in the reverse order i.e. capture using anti-Fc and detect using anti-Fab.
• the assay may be conducted in any suitable format, such as a conventional ELISA or Meso Scale Discovery format.
• the sample may include intermediate fragments such as scIgG in which only one heavy chain is cleaved, and the F(ab') 2 remains attached to the other, intact heavy chain.
• the scIgG fragment may be incorrectly identified by the assay as an intact IgG.
• the method may include a complimentary step of assessing the sizes of the fragments present in the sample. Since there are no disulphide bridges between the heavy chains below the hinge region, the Fc-part of the heavy chain in an scIgG fragment will separate from the intact heavy-chain under denaturating conditions as an approximately 20-25 kDa protein.
• the different fragment sizes can be detected and quantified using any suitable method, such as SDS-PAGE.
• a specific embodiment of the method, including the optional complimentary step is described in Example 1 (see Efficacy assessment ).
• the method is particularly useful for assessing the efficacy of IdeS in a clinical setting.
• a serum sample may be assayed for the presence of IgG molecules which possess either normal or truncated glycans, or for the glycan fragments that result from cleavage. This may be achieved by any suitable method, such as by separating the molecules and/or fragments based on molecular weight, e.g. by mass spectrometry or SDS-PAGE, or by specific detection of the molecules or fragments, e.g. by ELISA.
• the lower limit of the time interval between steps (a) and (b) may be selected from: at least 30 minutes, at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, or at least 6 hours.
• the lower limit may be shorter than any of the above should it be determined that Fc receptor binding by substantially all IgG molecules present in the serum of the subject has been eliminated at an earlier time point.
• the upper limit of the time interval between steps (a) and (b) may be selected independently of the lower limit, and may be determined by the time that it takes for endogenous production of IgG to begin to replace or to completely replace the IgG molecules that were present in the serum of the subject prior to carrying out the method. This may be determined by testing a serum sample taken from the individual and applying any suitable assay, such as those described above with respect to the lower limit. Newly-synthesised IgG typically starts to reappear in serum within 3-4 days, with total replacement complete by around 3 weeks (21 days).
• the upper limit of the time interval between steps (a) and (b) may be selected independently from the lower limit, and may be selected from: at most 21 days, at most 18 days, at most 14 days, at most 13 days, at most 12 days, at most 11 days, at most 10 days, at most 9 days, at most 8 days, at most 7 days, at most 6 days, at most 5 days, at most 4 days, at most 3 days, at most 2 days, at most 24 hours, at most 18 hours, at most 12 hours, at most 10 hours, at most 8 hours, at most 7 hours, at most 6 hours, at most 5 hours, at most 4 hours, at most 3 hours, at most 2 hours, or at most 1 hour.
• the time interval between steps (a) and (b) is at most 24 hours, more preferably at most 12 hours, most preferably at most 6 hours, so that steps (a) and (b) may be carried out on the same day or during the same visit to a treatment centre.
• the time interval between steps (a) and (b) should be long enough for the agent administered in step (a) to eliminate Fc receptor binding by substantially all IgG molecules present in the serum of the subject, but is at most around 6 hours.
• the interval between steps (a) and (b) is preferably 30 minutes to 1 hour, 30 minutes to 2 hours, 30 minutes to 3 hours, 30 minutes to 4 hours, 30 minutes to 5 hours, 30 minutes to 6 hours, 1 to 2 hours, 1 to 3 hours, 1 to 4 hours, 1 to 5 hours, 1 to 6 hours, 2 to 3 hours, 2 to 4 hours, 2 to 5 hours, 2 to 6 hours, 3 to 4 hours, 3 to 5 hours, 3 to 6 hours, 4 to 5 hours, 4 to 6 hours, or 5 to 6 hours.
• step (a) an effective amount of an agent which reduces Fc receptor binding of serum IgG molecules in a subject is administered to the subject.
• effective amount it is meant that the amount of the agent is sufficient to eliminate Fc receptor binding by substantially all IgG molecules present in the serum of the subject.
• the agent is typically a protein, typically of bacterial origin.
• the agent may be a protein which has IgG cysteine protease activity, preferably cleaving in the hinge region of the immunoglobulin molecule.
• IdeS I mmunoglobulin G -degrading e nzyme of S. pyogenes .
• IdeS is a streptococcal protease with a unique degree of specificity; it cleaves Immunoglobulin G (IgG) antibodies but no other substrate (including IgA, IgD, IgE and IgM).
• IdeS cleaves human IgG into F(ab') 2 and Fc fragments at a defined site COOH-terminally of the hinge region (see Figure 1 ).
• the mature sequence of IdeS is provided as SEQ ID NO: 1.
• the agent may be a protein comprising or consisting of the amino acid sequence of SEQ ID NO: 1, or may be a homologue thereof from an alternative bacterium.
• the agent may be a variant of the IdeS protein which comprises or consists of any amino acid sequence which has at least 80%, 85%, 90% or 95% identity with SEQ ID NO: 1 and has IgG cysteine protease activity.
• a preferred variant is the protein MAC2, the full sequence of which is available as Genbank Accession no. AFC67907.1.
• the sequence of MAC2 without signal sequence is provided as SEQ ID NO: 3.
• the agent may be a protein comprising or consisting of the amino acid sequence of SEQ ID NO: 3, or may be a homologue thereof from an alternative bacterium.
• a variant of the IdeS protein may comprise or consist of an amino acid sequence in which up to 1, 2, 3, 4, 5, 10, 20, 30 or more, amino acid substitutions, insertions or deletions have been made relative to the amino acid sequence of SEQ ID NO: 1, provided the variant has IgG cysteine protease activity.
• Said amino acid substitutions are preferably conservative. Conservative substitutions replace amino acids with other amino acids of similar chemical structure, similar chemical properties or similar side-chain volume.
• the amino acids introduced may have similar polarity, hydrophilicity, hydrophobicity, basicity, acidity, neutrality or charge to the amino acids they replace.
• the conservative substitution may introduce another amino acid that is aromatic or aliphatic in the place of a pre-existing aromatic or aliphatic amino acid.
• amino acids are well-known in the art and may be selected in accordance with the properties of the 20 main amino acids as defined in Table 1 below. Where amino acids have similar polarity, this can be determined by reference to the hydropathy scale for amino acid side chains in Table 2.
• Table 1 Chemical properties of amino acids Ala aliphatic, hydrophobic, neutral Met hydrophobic, neutral Cys polar, hydrophobic, neutral Asn polar, hydrophilic, neutral Asp polar, hydrophilic, charged (-) Pro hydrophobic, neutral Glu polar, hydrophilic, charged (-) Gln polar, hydrophilic, neutral Phe aromatic, hydrophobic, neutral Arg polar, hydrophilic, charged (+) Gly aliphatic, neutral Ser polar, hydrophilic, neutral His aromatic, polar, hydrophilic, charged (+) Thr polar, hydrophilic, neutral Ile aliphatic, hydrophobic, neutral Val aliphatic, hydrophobic, neutral Lys polar, hydrophilic, charged(+) Trp aromatic, hydrophopho
• the agent may be a protein, which comprises or consists of a fragment of SEQ ID NO: 1 or SEQ ID NO: 3, and has IgG cysteine protease activity, preferably wherein said fragment is 100 to 300, 150 to 300 or 200 to 300 amino acids in length.
• the fragment may be created by the deletion of one or more amino acid residues of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 3. Up to 1, 2, 3, 4, 5, 10, 20, 30, 40 or 50 residues may be deleted, or more. The deleted residues may be contiguous with each other.
• the agent may be a protein which has IgG endoglycosidase acitivty, preferably cleaving the glycan moiety at Asn-297 (Kabat numbering) in the Fc region of IgG.
• IgG IgG endoglycosidase acitivty
• EndoS Endo glycosidase of S . pyogenes
• EndoS hydrolyzes the ⁇ -1,4-di- N -acetylchitobiose core of the asparagine-linked glycan of normally-glycosylated IgG (see Figure 18 ).
• the mature sequence of EndoS is provided as SEQ ID NO: 2.
• the agent may be a protein comprising or consisting of the amino acid sequence of SEQ ID NO: 2, or may be a homologue thereof from an alternative bacterium, such as Streptococcus equi or Streptococcus zooepidemicus, or Corynebacterium pseudotuberculosis, Enterococcus faecalis, or Elizabethkingia meningoseptica.
• the agent may be CP40, EndoE, or EndoF 2 .
• the agent may be a variant of the EndoS protein which comprises or consists of any amino acid sequence which has at least 80%, 85%, 90% or 95% identity with SEQ ID NO: 2 and has IgG endoglycosidase activity.
• a variant of the EndoS protein may comprise or consist of an amino acid sequence in which up to 1, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, or more, amino acid substitutions, insertions or deletions have been made relative to the amino acid sequence of SEQ ID NO: 2, provided the variant has IgG endoglycosidase activity.
• Said amino acid substitutions are preferably conservative. Conservative substitutions are as defined above in respect of SEQ ID NO: 1.
• the agent may be a protein which comprises or consists of a fragment of SEQ ID NO: 2 and has IgG enodglycosidase activity, preferably wherein said fragment is 400 to 950, 500 to 950, 600 to 950, 700 to 950 or 800 to 950 amino acids in length.
• a preferred fragment consists of amino acids 1 to 409 of SEQ ID NO: 2, which corresponds to the enzymatically active ⁇ -domain of EndoS generated by cleavage by the streptococcal cysteine proteinase SpeB.
• the fragment may be created by the deletion of one or more amino acid residues of the amino acid sequence of SEQ ID NO: 1. Up to 1, 2, 3, 4, 5, 10, 20, 30, 40, 50, 100, 200, 300, 400, 500 or 550 residues may be deleted, or more. The deleted residues may be contiguous with other.
• Any fragment or variant of SEQ ID NO: 2 preferably includes residues 191 to 199 of SEQ ID NO: 2, i.e. Leu-191, Asp-192, Gly-193, Leu-194, Asp-195, Val-196, Asp-197, Val-198 and Glu-199 of SEQ ID NO: 1.
• These amino acids constitute a perfect chitinase family 18 active site, ending with glutamic acid.
• the glutamic acid in the active site of chitinases is essential for enzymatic activity.
• a variant of SEQ ID NO: 2 contains Glu-199 of SEQ ID NO: 2.
• the variant of SEQ ID NO: 2 may contain residues 191 to 199 of SEQ ID NO: 2 having one or more conservative substitutions, provided that the variant contains Glu-199 of SEQ ID NO: 2.
• the agent is preferably administered by intravenous infusion, but may be administered by any suitable route including, for example, intradermal, subcutaneous, percutaneous, intramuscular, intra-arterial, intraperitoneal, intraarticular, intraosseous or other appropriate administration routes.
• the amount of said agent that is administered may be between 0.01mg/kg BW and 2mg/kg BW, between 0.04 and 2mg/kg BW, between 0.12mg/kg BW and 2mg/kg BW, prefereably between 0.24mg/kg and 2mg/kg BW and most preferably between 1mg/kg and 2mg/kg BW.
• the agent may be present in a substantially isolated form.
• It may be mixed with carriers or diluents (as discussed below) which will not interfere with the intended use and still be regarded as substantially isolated. It may also be in a substantially purified form, in which case it will generally comprise at least 90%, e.g. at least 95%, 98% or 99%, of the protein in the preparation.
• the agent is preferably administered together with one or more pharmaceutically acceptable carriers or diluents and optionally one or more other therapeutic ingredients.
• the carrier (s) must be 'acceptable' in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
• carriers for injection, and the final formulation are sterile and pyrogen free.
• Formulation of a suitable composition can be carried out using standard pharmaceutical formulation chemistries and methodologies all of which are readily available to the reasonably skilled artisan.
• the agent can be combined with one or more pharmaceutically acceptable excipients or vehicles.
• auxiliary substances such as wetting or emulsifying agents, pH buffering substances and the like, may be present in the excipient or vehicle.
• excipients, vehicles and auxiliary substances are generally pharmaceutical agents that do not induce an immune response in the individual receiving the composition, and which may be administered without undue toxicity.
• Pharmaceutically acceptable excipients include, but are not limited to, liquids such as water, saline, polyethyleneglycol, hyaluronic acid, glycerol, thioglycerol and ethanol.
• Pharmaceutically acceptable salts can also be included therein, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like.
• mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like
• organic acids such as acetates, propionates, malonates, benzoates, and the like.
• compositions may be prepared, packaged, or sold in a form suitable for bolus administration or for continuous administration.
• injectable compositions may be prepared, packaged, or sold in unit dosage form, such as in ampoules or in multi-dose containers containing a preservative.
• Compositions include, but are not limited to, suspensions, solutions, emulsions in oily or aqueous vehicles, pastes, and implantable sustained-release or biodegradable formulations.
• Such compositions may further comprise one or more additional ingredients including, but not limited to, suspending, stabilizing, or dispersing agents.
• the active ingredient is provided in dry (for e.g., a powder or granules) form for reconstitution with a suitable vehicle (e.
• compositions may be prepared, packaged, or sold in the form of a sterile injectable aqueous or oily suspension or solution.
• This suspension or solution may be formulated according to the known art, and may comprise, in addition to the active ingredient, additional ingredients such as the dispersing agents, wetting agents, or suspending agents described herein.
• Such sterile injectable formulations may be prepared using a non-toxic parenterally-acceptable diluent or solvent, such as water or 1,3-butane diol, for example.
• a non-toxic parenterally-acceptable diluent or solvent such as water or 1,3-butane diol, for example.
• Other acceptable diluents and solvents include, but are not limited to, Ringer's solution, isotonic sodium chloride solution, and fixed oils such as synthetic mono-or di-glycerides.
• compositions which are useful include those which comprise the active ingredient in microcrystalline form, in a liposomal preparation, or as a component of a biodegradable polymer systems.
• Compositions for sustained release or implantation may comprise pharmaceutically acceptable polymeric or hydrophobic materials such as an emulsion, an ion exchange resin, a sparingly soluble polymer, or a sparingly soluble salt.
• step (b) a therapy or therapeutic agent is administered to the subject.
• the therapy or therapeutic agent will typically be administed or practised in precisely the same fashion as would have been used had step (a) not been conducted first.
• the therapeutic agent is an antibody which is administered for the treatement of cancer or another disease.
• the therapeutic agent may be intravenous immunoglobulin (IVIG).
• IVIG intravenous immunoglobulin
• the method may be alternatively described as a method for the treatment of cancer or another disease in a subject, the method comprising (a) administering to the subject an agent which reduces Fc receptor binding of serum IgG molecules in the subject; and (b) subsequently administering to the subject a therapeutically effective amount of an antibody which is a treatment for said cancer or said other disease; wherein:
• the disclosure also provides the agent for use in such a method for the treatment of cancer or another disease.
• the disclosure also provides use of the agent in the manufacture of a medicament for the treatment of cancer or another disease by such a method.
• the cancer may be Acute lymphoblastic leukemia, Acute myeloid leukemia, Adrenocortical carcinoma, AIDS-related cancers, AIDS-related lymphoma, Anal cancer, Appendix cancer, Astrocytoma, childhood cerebellar or cerebral, Basal cell carcinoma, Bile duct cancer, extrahepatic, Bladder cancer, Bone cancer, Osteosarcoma/Malignant fibrous histiocytoma, Brainstem glioma, Brain cancer, Brain tumor, cerebellar astrocytoma, Brain tumor, cerebral astrocytoma/malignant glioma, Brain tumor, ependymoma, Brain tumor, medulloblastoma, Brain tumor, supratentorial primitive neuroectodermal tumors, Brain tumor, visual pathway and hypothalamic glioma, Breast cancer, Bronchial adenomas/carcinoids, Burkitt lymphoma, Carcinoid tumor, Carcinoid tumor,
• the cancer is preferably prostate cancer, breast cancer, bladder cancer, colon cancer, rectal cancer, pancreatic cancer, ovarian cancer, lung cancer, cervical cancer, endometrial cancer, kidney (renal cell) cancer, oesophageal cancer, thyroid cancer, skin cancer, lymphoma, melanoma or leukemia.
• the antibody administered in step (b) is preferably specific for a tumour antigen associated with one or more of the above cancer types.
• Targets of interest for an antibody for use in the method include CD2, CD3, CD19, CD20, CD22, CD25, CD30, CD32, CD33, CD40, CD52, CD54, CD56, CD64, CD70, CD74, CD79, CD80, CD86, CD105, CD138, CD174, CD205, CD227, CD326, CD340, MUC16, GPNMB, PSMA, Cripto, ED-B, TMEFF2, EphA2, EphB2, FAP, av integrin, Mesothelin, EGFR, TAG-72, GD2, CA1X, 5T4, ⁇ 4 ⁇ 7 integrin, Her2.
• cytokines such as interleukins IL-I through IL- 13, tumour necrosis factors ⁇ & ⁇ , interferons ⁇ , ⁇ and ⁇ , tumour growth factor Beta (TGF- ⁇ ), colony stimulating factor (CSF) and granulocyte monocyte colony stimulating factor (GMCSF).
• TGF- ⁇ tumour growth factor Beta
• CSF colony stimulating factor
• GMCSF granulocyte monocyte colony stimulating factor
• Other targets are hormones, enzymes, and intracellular and intercellular messengers, such as, adenyl cyclase, guanyl cyclase, and phospholipase C.
• targets of interest are leukocyte antigens, such as CD20, and CD33.
• Drugs may also be targets of interest.
• Target molecules can be human, mammalian or bacterial.
• Other targets are antigens, such as proteins, glycoproteins and carbohydrates from microbial pathogens, both viral and bacterial, and tumors. Still other targets are described in U.S. 4,366,241 .
• another disease any other disease which is treatable by administration of an antibody.
• the other disease may be malignant ascites, in which case the antibody which is a treatment for the disease is typically catumaxomab or an antibody which binds to the same target as catumaxomab.
• the antibody may be attached directly or indirectly to a cytotoxic moiety or to a detectable label.
• the antibody may be administered via one or more routes of administration using one or more of a variety of methods known in the art.
• the route and/or mode of administration will vary depending upon the desired results.
• Preferred routes of administration for antibodies include intravenous, intramuscular, intradermal, intraperitoneal, subcutaneous, spinal or other parenteral routes of administration, for example by injection or infusion.
• parenteral administration as used herein means modes of administration other than enteral and topical administration, usually by injection.
• an antibody can be administered via a non-parenteral route, such as a topical, epidermal or mucosal route of administration.
• Local administration is also preferred, including peritumoral, juxtatumoral, intratumoral, intralesional, perilesional, intra cavity infusion, intravesicle administration, and inhalation.
• a suitable dosage of an antibody may be determined by a skilled medical practitioner. Actual dosage levels of an antibody may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
• the selected dosage level will depend upon a variety of pharmacokinetic factors including the activity of the particular antibody employed, the route of administration, the time of administration, the rate of excretion of the antibody, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compositions employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
• a suitable dose of an antibody may be, for example, in the range of from about 0.1 ⁇ g/kg to about 100mg/kg body weight of the patient to be treated.
• a suitable dosage may be from about 1 ⁇ g/kg to about 10mg/kg body weight per day or from about 10 ⁇ g/kg to about 5 mg/kg body weight per day.
• Dosage regimens may be adjusted to provide the optimum desired response (e.g ., a therapeutic response).
• a single bolus may be administered, or step (b) of the method may comprise several divided doses administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation, provided the required interval between steps (a) and (b) is not exceeded.
• parenteral compositions in dosage unit form for ease of administration and uniformity of dosage.
• Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
• the antibody of step (b) may be administered in combination with chemotherapy or radiation therapy.
• the method may further comprises the administration of an additional anti-cancer antibody or other therapeutic agent, which may be administered together with the antbody of step (b) in a single composition or in separate compositions as part of a combined therapy.
• the antibody of step (b) may be administered before, after or concurrently with the other agent.
• Preferred antibodies include Natalizumab, Vedolizumab, Belimumab, Atacicept, Alefacept, Otelixizumab, Teplizumab, Rituximab, Ofatumumab, Ocrelizumab, Epratuzumab, Alemtuzumab, Abatacept, Eculizumab, Omalizumab, Canakinumab, Meplizumab, Reslizumab, Tocilizumab, Ustekinumab, Briakinumab, Etanercept, Inlfliximab, Adalimumab, Certolizumab pegol, Golimumab, Trastuzumab, Gemtuzumab, Ozogamicin, Ibritumomab, Tiuxetan, Tostitumomab, Cetuximab, Bevacizumab, Panitumumab, Denosumab, Ipilimumab, Brentuximab
• the therapy is an organ transplant.
• the organ may be selected from kidney, liver, heart, pancreas, lung, or small intestine.
• the subject to be treated may preferably be sensitized or highly sensitised.
• sensitized it is meant that the subject has developed antibodies to human major histocompatibility (MHC) antigens (also referred to as human leukocyte antigens (HLA)).
• MHC human major histocompatibility
• HLA human leukocyte antigens
• the anti-HLA antibodies originate from allogenically sensitized B-cells and are usually present in patients that have previously been sensitized by blood transfusion, previous transplantation or pregnancy (Jordan et al., 2003).
• Whether or not a potential transplant recipient is sensitized may be determined by any suitable method.
• a Panel Reactive Antibody (PRA) test may be used to determine if a recipient is sensitized.
• a PRA score >30% is typically taken to mean that the patient is "high immulogic risk” or "sensitized”.
• a cross match test may be conducted, in which a sample of the potential transplant donor's blood is mixed with that of the intended recipient.
• a positive cross-match means that the recipient has antibodies which react to the donor sample, indicating that the recipient is sensitized and transplantation should not occur.
• Cross-match tests are typically conducted as a final check immediately prior to transplantation.
• DSA donor specific antibodies
• the median time on the waiting list for renal transplantation in 2001-2002 was 1329 days for those with Panel Reactive Antibody (PRA) score 0-9%, 1920 days for those with PRA 10-79%, and 3649 days for those with PRA 80% or greater (OPTN-database, 2011).
• PRA Panel Reactive Antibody
• One accepted strategy to overcome the DSA barrier is to apply plasma exchange or immune adsorption, often in combination with e.g. intravenous gamma globulin (IVIG) or Rituximab, to lower the levels of DSA to a level where transplantation can be considered (Jordan et al., 2004; Montgomery et al., 2000; Vo et al., 2008a; Vo et al., 2008b).
• IVIG intravenous gamma globulin
• Rituximab e.g. intravenous gamma globulin
• plasma exchange, immune adsorption and IVIG treatments have the disadvantage of being inefficient and requiring rigorous planning since they involve repeated treatments over an extended period of time.
• an organ from a deceased donor becomes available it has to be transplanted within hours since prolonged cold ischemia time is one of the most important risk factors for delayed graft function and allograft loss in renal transplantation (Ojo et al., 1997).
• the method of the present invention allows the rapid, temporary and safe removal of DSAs in a potential transplant recipient.
• Administering the agent just prior to transplantation has the capacity to effectively desensitize a highly sensitized patient, thereby allowing transplantation and avoiding acute antibody-mediated rejection.
• a single dose of agent prior to transplantation will enable transplantation of thousands of patients with donor specific IgG antibodies.
• the method may be alternatively described as a method for the treatment of organ failure in a subject, the method comprising (a) administering to the subject an agent which reduces Fc receptor binding of serum IgG molecules in the subject; and (b) subsequently transplanting a replacement organ into the subject; wherein:
• This embodiment may be described as a method for preventing rejection of a transplanted organ in a subject, particularly acute antibody-mediated transplant rejection, the method comprising, at least 2 hours and at most 21 days prior to transplantation of the organ, administering to the subject an agent which reduces Fc receptor binding of serum IgG molecules in the subject, wherein the amount of said agent administered is sufficient to eliminate Fc receptor binding by substantially all IgG molecules present in the serum of the subject.
• administration of the agent and subsequent transplantation are separated by a time interval which is equivalent to the time interval between steps (a) and (b) in the alternative phrasings of the method presented above.
• the various upper and lower limits for the time interval between steps (a) and (b) described above apply equally to this time interval.
• the time interval is short enough to allow the method to be conducted during a single hospital visit.
• preferred intervals are 1 to 6 hours or 1 to 12 hours.
• the disclosure also provides use of the agent in such a method of treating organ failure or preventing transplant rejection, particularly acute antibody-mediated transplant rejection.
• the disclosure also provides use of the agent in the manufacture of a medicament for the treatment of organ failure or for the prevention of transplant rejection by such a method.
• the method of the disclosure may additionally comprise a step conducted at or immediately prior to transplantation, which step comprises induction suppression of T cells and/or B cells in the patient.
• Said induction suppression may typically comprise administering an effective amount of an agent which kills or inhibits T cells, and/or administering an effective amount of an agent which kills or inhibits B cells.
• Agents which kill or inhibit T cells include Muromonab, Basiliximab, Daclizumab, an antithymocyte globulin (ATG) antibody and a lymphocyte immune globulin, anti-thymocyte globulin preparation (ATGAM).
• Rituximab is known to kill or inhibit B cells.
• the disclosure also provides a method for removing antibodies or reducing the effects of antibodies in a subject.
• the antibodies to be affected by the method are typically pathogenic autoantibodies.
• the method comprises a first step, referred to as step (a) and an optional second step, referred to as step (b).
• Step (a) comprises administering to the subject an agent which reduces Fc receptor binding of serum IgG molecules in the subject.
• the amount of the agent administered is preferably sufficient to eliminate Fc receptor binding by substantially all IgG molecules present in the serum of the subject.
• step (b) comprises, subsequent to step (a), subjecting the subject to a treatment which removes endogenous antibodies; wherein said treatment which removes endogenous antibodies is plasmapharesis or immunoadsoprtion, or is administration of an agent (such as an anti-FcRn antibody) which prevents recycling of antibodies in serum by the FcRn receptor, thereby reducing half-life, and wherein steps (a) and (b) are separated by a time interval of at least 2 weeks.
• a treatment which removes endogenous antibodies is plasmapharesis or immunoadsoprtion, or is administration of an agent (such as an anti-FcRn antibody) which prevents recycling of antibodies in serum by the FcRn receptor, thereby reducing half-life
• the method may further comprise repeating step (a).
• Step (a) is preferably only repeated if the patient has a low level of anti-agent antibody responses.
• the quantity of anti-agent IgG molecules in the serum of a patient may be determined by any suitable method, such as an agent specific CAP FEIA (ImmunoCAP) test.
• a repetition of step (a) would only be conducted if the result of the CAP FEIA is below a threshold to be determined by the clinician.
• step (a) should be repeated no more frequently than once every 6 months.
• the affected by the method may typically pathogenic autoantibodies specific for an autoantigen which is targeted in an autoimmune disease mediated wholly or in part by autoantibodies.
• Table 3 sets out a list of such diseases and the associated autoantigens.
• DISEASE AUTOANTIGENS Addison's disease Steroid 21-hydroxylase, 17 alpha-Hydroxylase (17OH) and side-chain-cleavage enzyme (P450scc), Thyroperoxidase, thyroglobulin and H+/K(+)- Anti-GBM glomerulonephritis (related to Goodpasteur)
• ANCA associated vasculitides ANCA associated vasculitis
• ANCA associated vasculitis Wegener granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis
• beta2GPI cardiolipin
• beta2-glycoprotein I and (beta2GPI) Autoimmune bullous skin diseases (Pemphigus).
• Pemphigus foliaceus (PF) fogo selvagem (FS)(endemic form), pemphigus vulgaris (PV) IgG against keratinocytes.
• PF Pemphigus foliaceus
• FS fogo selvagem
• PV pemphigus vulgaris
• Dsg desmosomal Cadherins
• AIHA Autoimmune hemolytic anemia
• AIH Self-antigens on red-blood-cells
• AIH Autoimmune hepatitis Actin
• antinuclear antibody ANA
• smooth muscle antibody SMA
• liver/kidney microsomal antibody LLM-1
• anti soluble liver antigen SLA/LP
• anti-mitochondrial antibody AMA
• CYP2D6, CYP2C9-tienilic acid UGT1A, CYP1A2, CYP2A6, CYP3A, CYP2E1, CYP11A1, CYP17 and CYP21
• AIN Autoimmune neutropenia
• AIN FcgRIIIb Bullous pemphigoid
• BP Hemidesmosomal proteins BP230 and BP180 (type XVII collagen)
• laminin 5 the alpha6 subunit of the integrin alpha6beta4 and
• TSHR Thyrotropin receptor
• TPO Thyroid peroxidase
• GFS Guillain-Barré syndrome
• Acute inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN) Gangliosides GM1, GM1b, GD1a, and GalNAc-GD1a, glycosphingolipid, myelin proteins PMP22 and P0 Hemophilia - Acquired FVIII deficiency Factor VIII Idiopathic thrombocytopenic purpura (ITP) Platelet glycoprotein (GP) IIb-IIIa and/or GPIb-IX Lambert-Eaton myasthenic syndrome (LEMS) voltage gated calcium channels Mixed Connective Tissue Disease (MCTD) IgG directed against the spliceosome, U1-snRNP Multiple Myeloma Multiple Myeloma antigens Myasthenia gravis Acetylcholine receptors (AchR), muscle-specific kinase (MuSK) Myocarditis, dilated cardiomyopathy (DCM)(congestive cardiomy
• SS cytokeratin Sjögren Syndrome
• SS-A Sjögren Syndrome antigen A
• La Sjögens syndrome antigen B(SS-B)
• p80 coilin antinuclear antibodies, anti-thyroid, anti-centromere antibodies (Raynaud's phenomenon), anti-carbonic anhydrase II (distal renal tubular acidosis), anti-mitochondrial antibodies (liver pathology), cryoglobulins (evolution to non-Hodgkin's lymphoma).
• alpha- and beta-fodrin islet cell autoantigen
• PARP poly(ADP)ribose polymerase
• NuMA NuMA
• Golgins Golgins
• NOR-90 M3-muscarinic receptor SLE including Lupus nephritis Autoantibodies to nuclear constituents (e.g. dsDNA and nucleosomes), dsDNA, PARP, Sm, PCDA, rRNA Ribosome P proteins, C1q Stiff-person syndrome (SPS) glutamic acid decarboxylase (GAD), amphiphysin.
• SPS Stiff-person syndrome
• GAD glutamic acid decarboxylase
• Systemic sclerosis DNA-topoisomerase I (Scl-70), U3 snRNP, U2 snRNP, 7-2 RNP, NOR-90, centromere-associated proteins, and nucleolar antigens ,Anti-Th/To, Anti-RNA polymerase I/III, Anti-PDGF receptor, Anti-fibrillin-1, M3-muscarinic receptor, Transplant rejection Transplant rejection antigens
• the method may be alternatively described as a method for the treatment of an autoimmune disease in a subject, the method comprising (a) administering to the subject an agent which reduces Fc receptor binding of serum IgG molecules in the subject; and optionally (b) subsequently administering to the subject a therapeutically effective amount of an antibody which is a treatment for said cancer or autoimmune disease; wherein the amount of said agent administered is sufficient to eliminate Fc receptor binding by substantially all IgG molecules present in the serum of the subject; and steps (a) and (b) are separated by a time interval of at least 2 hours and at most 21 days.
• the disclosure also provides the agent for use in such a method for the treatment of autoimmune disease.
• the disclosure also provides use of the agent in the manufacture of a medicament for the treatment of autoimmune disease by such a method.
• the autoimmune disease is preferably a chronic autoimmune disease which is mediated wholly or in part by autoantibodies.
• the autoimmune disease may be one of the diseases listed in Table 3.
• the agent administered in step (a) typically does not act only on serum IgG molecules.
• the inventors have also made the surprising discovery that the agent may also act upon membrane bound IgG molecules which are present as part of a B cell receptor complex (BCR).
• BCR B cell receptor complex
• the BCR contains one ligand binding and one signalling part.
• the ligand-binding part consists of an antibody with a transmembrane domain and the signalling part consists of a heterodimer called Ig- ⁇ /Ig- ⁇ (CD79a/CD79b).
• the CD79 proteins span the plasma membrane and have a cytoplasmic tail bearing an immunoreceptor tyrosine-based activation motif (ITAM).
• ITAM immunoreceptor tyrosine-based activation motif
• SRC family kinase LYN Upon receptor ligation ITAM is phosphorylated by the SRC family kinase LYN and recruits the spleen tyrosine kinase (SYK) to the receptor.
• signalosome which assembles signalling molecules, such as phospholipase-Cy2 (PLC ⁇ 2), (phosphoinositide 3-kinase (PI3K), Bruton's tyrosine kinase (BTK), VAV1 and adaptor molecules.
• PLC ⁇ 2 and PI3K Two fundamental and intensively studied intermediates in the BCR signalling cascades, PLC ⁇ 2 and PI3K, generate key second messengers, which in turn, activate I ⁇ B kinase (IKK) and extracellular-signal regulated kinases (ERK1/2; AKA MAPK3 and 1).
• IKK I ⁇ B kinase
• ERK1/2 extracellular-signal regulated kinases
• B-cell proliferation, survival, differentiation and cell death are closely regulated by the balance between these signalling events.
• na ⁇ ve mature B-cells leave the bone marrow, go through somatic hyper mutation in germinal centres and class switching before becoming high affinity long-lived plasma cells and memory B-cells ready to respond heavily when activated by antigenic stimulation.
• Memory B-cells respond to antigen through binding to the BCR and a substantial portion of memory B-cells in circulation have an IgG-type of BCR.
• the agent administered in step (a) of a method of the invention may also act upon the IgG part of the BCR of memory B-cells and may inhibit the normal activation of these cells by ligand binding.
• This interval typically ends at around 12 hours after completion of step (a), but may be longer.
• levels of intact membrane bound IgG (and thus normal BCR) have recovered, typically as a result of membrane turnover in the affected cell.
• step (a1) is conducted after step (a) and, if step (b) is present, before step (b) in a method of the invention.
• Step (b) will then typically be conducted as soon as is possible or practical after step (a1).
• Step (a1) may be conducted (i) in the interval after step (a) but before the recovery of levels of intact membrane bound IgG on cell surfaces in the subject, or (ii) in the interval after (i) but before newly-synthesised IgG starts to re-appear in serum of the subject.
• the recovery of the level of intact membrane-bound IgG or the re-appearance of serum IgG may be determined by any suitable method. Exemplary methods are described in the Examples.
• step (a1) is conducted in interval (i), it may be conducted at up to 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours,12 hours, 16 hours or 24 hours after step (a), preferably at up to 1 or 2 hours after step (a).
• the interval of (ii) starts at the end of the interval of (i) and typically ends 3 or 4 days after step (a).
• the interval of (ii) is thus typically at most from 12 hours to 4 days (96 hours) after step (a).
• step (a1) is conducted in interval (ii) it is conducted between 12 hours and 96 hours after step (a1), and may be conducted between 12 hours and 24 hours, between 12 hours and 48 hours, or between 12 hours and 72 hours after step (a).
• conducting step (a1) between 12 hours and 24 hours aftert step (a) is preferred.
• step (a1) is conducted in interval (i), it typically comprises administration of an agent which specifically targets an epitope present on the IgG or IgG fragment which results from the action on a B cell of the agent of step (a).
• step (a1) may comprise administration of an agent which specifically binds to a membrane bound Fc fragment (such as that produced by the action of IdeS) or which specifically binds to a membrane bound IgG with altered glycosylation (such as that produced by the action of EndoS).
• the epitope may be newly created by the action of the agent of step (a), or may be an epitope which is already present in intact IgG, provided that it is retained by the IgG or IgG fragment which results from the action of the agent of step (a).
• the invention may also provide a method in which an additional step (a1) is conducted after step (a) and, if step (b) is present, before step (b), wherein step (a1) comprises administering to the subject an agent which specifically binds to an epitope produced by the action of the agent administered in step (a) on membrane-bound IgG in the BCR complex, wherein said administering is conducted in an interval after step (a) but before the level of intact membrane-bound IgG in BCR complexes has recovered to the same level as was present before step (a). That is interval (i) as described above.
• the epitope may be, for example, a membrane-bound Fc fragment (such as that produced by the action of IdeS).
• the agent administered in step (a1) of said method may be any agent which specifically binds to the epitope, such as an antibody. Binding of the agent will typically result in reduced activation and/or death of a cell upon which the target is present. Said cell is typically a memory B cell.
• the agent may optionally be conjugated to a cytotoxin (suitable examples include those listed in Table 4), radioisotope or other moiety to promote said reduced activation or death of said cell.
• administration of an agent in step (a1) typically results in death of memory B cells which display an IgG molecule which has been altered by the action of the agent of step (a).
• the inclusion of step (a1) may increase the beneficial effects of a method of the invention, for example by prolonging or maintaining the absence of serum IgG molecules.
• step (a1) is conducted in interval (ii), it typically comprises administration of an agent which specifically targets intact membrane bound IgG. Said agent will only affect memory B cells for which levels of membrane bound IgG in the BCR complex have recovered. Within this interval, all other forms of intact IgG (e.g. circulating IgG or IgG bound to effector cells by Fc receptors in the cell membrane) will have been removed by the action of the agent administered in step (a) and the resulting fragments will have been cleared. Thus, the agent administered in step (a1) may be used to target all memory B cells which have recovered an intact BCR.
• an agent which specifically targets intact membrane bound IgG Said agent will only affect memory B cells for which levels of membrane bound IgG in the BCR complex have recovered.
• all other forms of intact IgG e.g. circulating IgG or IgG bound to effector cells by Fc receptors in the cell membrane
• the agent administered in step (a1) may be used to target all memory B cells which have recovered an intact BCR.
• the agent may be used to target the specific Fab region of the BCR of memory B cells which are specific for a particular antigen, that is the agent administered in step (a1) may be anti-idiotypic.
• the agent administered in step (a1) may be used to target the Fab region of donor specific antibodies in a transplant recipient, or the Fab region of antibodies specific for autoimmune antigens in an autoimmune patient, such as a patient suffering from a disorder as listed in Table 3.
• the invention may also provide a method in which an additional step (a1) is conducted after step (a) and before step (b) if step (b) is present, wherein step (a1) comprises administering to the subject an agent which specifically binds to an epitope of intact, membrane-bound IgG, wherein said administering is conducted in the interval after step (a) in which the level of intact membrane-bound IgG in BCR complexes has returned to a level similar to, substantially the same as, or the same as the level that as was present before step (a), but newly-synthesised IgG has not yet re-appeared in serum. That is interval (ii) as described above.
• the agent administered in step (a1) of said method may be any agent which specifically binds to the epitope, such as an antibody. Binding of the agent will typically result in reduced activation and/or death of a cell upon which the target is present.
• the agent may optionally be conjugated to a cytotoxin (suitable examples include those listed in Table 4), radioisotope or other moiety to promote said reduced activation or death of said cell.
• administration of an agent in step (a1) may result in the death of all memory B cells which display an intact membrane bound IgG molecule. Alternatively it may result in the death only of memory B cells which display a particular specificity of membrane bound IgG molecule.
• step (a1) may increase the beneficial effects of a method of the invention, for example by prolonging or maintaining the absence of all serum IgG molecules, or prolonging or maintaing the absence of a specific sub-set of serum IgG molecules specific for a particular target.
• the latter may be particularly advantageous in that it will allow for the selective removal of unwanted subsets of IgG molecules from the newly-synthesised population of IgG in the serum of the subject to which the method of the invention is applied.
• kits suitable for use in a method of the invention the kit containing an amount of an agent which reduces Fc receptor binding of serum IgG molecules in a subject, which amount is sufficient to eliminate Fc receptor binding by all or substantially all IgG molecules present in the serum of a subject.
• kits of the disclosure may additionally comprise one or more other reagents or instruments which enable any of the embodiments mentioned above to be carried out.
• reagents or instruments include one or more of the following: a therapeutically effective amount of a therapeutic agent, which is an antibody, suitable buffer(s) (aqueous solutions), means to administer the agent to a subject as an intravenous infusion (such as a vessel or an instrument comprising a needle).
• a therapeutically effective amount of a therapeutic agent which is an antibody
• suitable buffer(s) aqueous solutions
• Reagents may be present in the kit in a dry state such that a fluid sample resuspends the reagents.
• the kit may also, optionally, comprise instructions to enable the kit to be used in the method of the invention or details regarding which patients the method may be used for.
• IdeS cleaved the complete plasma pool of IgG within 5 minutes upon IdeS administration with ⁇ 1% remaining IgG one day after treatment.
• the IgG level reached its lowest level 24-48 hours after IdeS-treatment and then gradually increased during the following days. Normal IgG levels were restored approximately 3 weeks after a single IdeS dose.
• the end-products i.e. the F(ab') 2 - and Fc-fragments, had significantly shorter half-lives compared to intact IgG and only low levels were detectable the day after a single dose of IdeS.
• IdeS had a rapid distribution, showed dose proportional pharmacokinetics and a multi-phase elimination with a plasma half-life of approximately 1 hour in rabbits. Based on repeat dose toxicology studies the No Observed Adverse Effect Level (NOAEL) for IdeS was set to 2 mg/kg body weight (BW). Data not shown.
• NOAEL No Observed Adverse Effect Level
• the diluted infusion solution of the GMP-produced IdeS (Hansa Medical AB, Sweden) was prepared in a phosphate buffered isotonic salt solution by the hospital pharmacy in an infusion syringe with an infusion set including a 0.2 ⁇ m filter (B. Braun, Germany).
• the selected starting dose of 0.010 mg/kg BW was 10-times below the pre-clinically determined Minimal Anticipated Biological Effect Level (MABEL) and 200-times below the No Observed Adverse Effect Level (NOAEL) determined during animal toxicology.
• MABEL Minimal Anticipated Biological Effect Level
• NOAEL No Observed Adverse Effect Level
• the subjects had to be healthy according to the screening medical examination, aged 18 - 45 years, have suitable veins for cannulation, a body mass index (BMI) between 19 and 30 kg/m 2 and weigh 50-100 kg.
• BMI body mass index
• Subjects excluded from the study were those who had (or had a history of) any clinically significant immunodeficiency including but not limited to immunoglobulin A deficiency, had elevated levels of anti-IdeS IgG (>15 mg/L), tested positive for serum hepatitis B surface antigen, hepatitis C antibody, human immunodeficiency virus (HIV), ongoing tuberculosis, ongoing syphilis, active herpes simplex or herpes zoster infection during screening.
• immunoglobulin A deficiency had elevated levels of anti-IdeS IgG (>15 mg/L)
• HIV human immunodeficiency virus
• ongoing tuberculosis ongoing tuberculosis
• ongoing syphilis active
• Each subject had a three days admission period at the Clinical Trials Unit and was randomized to IdeS or placebo (phosphate buffered saline) and dosed the morning after admission. Two subjects in each dose group were dosed on the first day (one IdeS and one placebo) and the next subjects in the group were dosed after one week. After each cohort the Data Monitoring Committee assessed the safety data and decided the next dose level. The time from the last dose at one dose level to the initiation of next dose level was at least 14 days. The infusions were given during 30 minutes for the first two subjects in each group and during 15 minutes for subsequent subjects in that group. During the admission period intensive safety monitoring and serial blood samplings for safety, pharmacokinetics, efficacy and anti-drug antibodies were performed. The subjects were discharged on day 4 and conducted at least eight intermediate follow-up visits with medical examination and blood sampling until the end of study at day 64.
• Adverse events were collected from the time of admission and throughout the study period including the follow-up period. All information about an AE was recorded including description, start/stop time, common Toxicity Criteria grade (according to CTCAE), severity, causality (unlikely, possible or probable), action taken, discontinuation and outcome. Vital signs, body temperature, heart rate and supine blood pressure were recorded regularly during the admission period and at all subsequent visits. In addition, the subjects were monitored with a 5-lead telemetric ECG during the infusion and the following 24 hours. Safety samples for clinical chemistry, hematology, coagulation, safety biomarkers (IL-6, IL-8 and TNF ⁇ ) and plasma IgG were analyzed using routine methods at Labmedicin Sk ⁇ ne, Sweden. Urinalysis (U-glucose, U-hemoglobin and U-protein) was assessed using Multistix (Siemens, Germany).
• Blood samples intended for efficacy studies were collected in modified CAT serum BD vacutainers (BD Diagnostics, NJ, USA) containing 2 mM iodoacetic acid in order to prevent further proteolytic cleavage by IdeS. Blood sampling was performed at the following time-points: pre-dose, 1 minute before end of infusion (14 or 29 min), 5 minutes after end of infusion (20 or 35 min) and 45 minutes after end of infusion (1 h or 1 h and 15 min). In addition samples were collected 2, 6, 24, 48 and 72 hours after start of infusion as well as on day 7, 14, 21, 28 and 64 after infusion.
• Blood samples intended for pharmacokinetic studies were collected in regular serum BD vacutainers at the following time-points: pre-dose, 1 minute before end of infusion, 5 minutes after end of infusion, 45 min after end of infusion and 2, 6, 24, 48, 72 and 144 hours after dosing.
• Blood samples intended for anti-IdeS antibody analysis were collected in regular serum BD vacutainers at day 1 (pre-dose), 2 (24 h), 3 (48 h), 4 (72 h), 7 (1 week), 14, (2 weeks), 21 (3 weeks), 28 (4 weeks) and 64 (2 months). Outside the study protocol the subjects were asked for optional serum samples on day 182 (6 months) and 365 (1 year). All samples were stored below -60°C until analyzed.
• IdeS cleavage and processing of IgG was investigated with different methods; Enzyme-linked immune-sorbent assays (ELISAs) were used to determine IgG and IgG fragments in serum and to investigate the dynamics of the Fab- and Fc- containing fragments.
• the quantitative assays could not completely differentiate between the IdeS cleavage products; i.e. F(ab') 2 , Fc and single cleaved IgG (scIgG) (where one of the heavy chains is cleaved).
• the ELISA developed and performed by Covance Ltd, UK, measured intact IgG and scIgG.
• the Fab-ELISA measured all Fab-containing IgG fragments; i.e. intact IgG, scIgG and F(ab') 2 and the Fc-ELISA measured all Fc containing fragments; i.e. intact IgG, scIgG and free Fc.
• the Fc-ELISA used a goat anti-human IgG (Fc ⁇ fragment specific) F(ab') 2 fragment (#109-006-098 Jackson ImmunoResearch Labs Inc., PA, USA) as catcher antibody and a biotin conjugated goat anti-human IgG (Fc ⁇ fragment specific) F(ab') 2 fragment (#109 066 098 Jackson ImmunoResearch) as detector.
• Calibrator and QC-samples were prepared from human intravenous gamma globulin IVIg (Octagam ® ). All dilutions were performed in PBS + 0.1% BSA and the Nunc MaxiSorp ® flat-bottom 96-well microtiter plates (Nunc A/S, Roskilde, Denmark) were washed with PBS containing 0.05% Tween 20. The serum samples and QC-samples were analyzed in triplicates.
• TMB One component HRP Microwell substrate (TMBW-1000-01, BioFx Laboratories Inc., MD, USA) was used as a chromogenic substrate and the enzyme reaction was stopped by the addition of 0.5 M H 2 SO 4 .
• FIG. 19 A comparison of the Fab-ELISA and a conventional turbidimetric analysis of serum IgG is shown in Figure 19 .
• the turdidimetric assay detects only a small change in the level of intact IgG over time following IdeS treatment, because it cannot discriminate between F(ab') 2 and intact IgG.
• the Fab-ELISA shows almost complete removal and recovery of IgG levels in the same time period.
• the serum samples were also analyzed using qualitative SDS-PAGE analyses.
• the SDS-PAGE analyses were performed according to the manufacturer's instructions (Bio-Rad Laboratories, CA, USA). Briefly, 0.25 ⁇ l of serum was separated on 4-20% Mini-PROTEAN ® TGX TM precast gels (BioRad) at 200 V for 40 minutes under non-reduced conditions. SeeBlue MW standard (Life Technologies) and an in house prepared mix of human IgG, scIgG, F(ab') 2 and Fc were used as markers. The gels were stained with GelCode Blue stain reagent (Pierce, Thermo Fisher Scientific, MA, USA) according to the manufacturer's instructions and the gels were scanned.
• IdeS derived peptides i.e. AFPYLSTK, AIYVTDSDSNASIGMK, GGIFDAVFTR and LFEYFK
• LC-MS/MS assay a qualified LC-MS/MS assay. Samples were prepared for MS analysis as previously described (Karlsson et al. 2012).
• SRM selected reaction monitoring
• the raw data was processed and analyzed with SRM analysis software Skyline (MacLean et al. 2010) with manual validation and inspection of the results.
• the injection volume was 1 ⁇ l corresponding to 12.5 nl serum (i.e. 1 ⁇ g total protein).
• Un-normalized peptide Total Peak Areas from IdeS-spiked serum was used for fitting a linear regression curve (label-free protein quantification).
• the concentrations of the individual peptides in the unknown human samples were interpolated from the linear regression.
• a commercial equimolar mixture of tryptic peptides from 6 bovine proteins (6 Bovine Tryptic Digest Equal Molar Mix, Michrom Bioresources) was used as QC-sample and run every 4-6 analytical sample (Teleman et al. 2012).
• Serum concentration versus time data was analysed by non-compartmental analysis (NCA) in PhoenixTM WinNonlin ® version 6.3, build 6.2.0.495 (Pharsight ® , St. Louis, Missouri, USA). As no major deviations (> 20%) between nominal and actual sampling times and doses were observed, nominal sampling times and doses were used for the NCA calculations.
• the LC-MS/MS assay has not been validated and no formal lowest limit of detection (LLOQ) has been defined.
• LLOQ formal lowest limit of detection
• a cut off for the PK calculations was set to 24 hours post dose for all four peptides and individuals.
• a CAP-FEIA (ImmunoCAP) test for quantification of anti-IdeS specific IgG was developed by Thermo Fisher Scientific (Phadia ® ) in Uppsala, Sweden. Initial testing indicated that a 3-logaritmic measuring range was possible using the test and the limit of detection (LOD) for the IgG IdeS-specific CAP-FEIA assay was shown to be seven times below the suggested low assay cut-off (i.e. 2.0 mg/L). Analyses of the clinical samples were performed on a Phadia ® 250 instrument using the test with one replicate according to the Phadia ® 250 user manual. The test was intended for research use only.
• a research grade ELISA assay was developed at Hansa Medical AB in order to address antigen-specific efficacy at the end of the study.
• the subjects IgG-response against a vaccine included in the Swedish childhood vaccination schedule was utilized as a surrogate for lack of auto-antigens in the healthy subjects included in the phase 1 study.
• DTaP-IPV//PRP ⁇ T vaccine (Pentavac ® /Pentaxim ® -Sanofi Pasteur) was diluted 100-times in PBS prior to coating MaxiSorp plates (Nunc) at 4°C.
• a phagocytosis assay was developed with modifications from (Ackerman et al., 2011). Fluorescent neutravidin beads (#F8776, Molecular Probes) were coated over night with biotinylated anti-IgG CH1 (CaptureSelect, #710.3120.100 BAC B.V., Naarden, Netherlands) at 0.1 mg/ml.
• the CaptureSelect reagent is specific for human heavy chain IgG on the CH1 domain i.e. intact IgG, scIgG and F(ab') 2 fragments but not IgM will be captured by this protein.
• Coated beads were washed and mixed with 1:100 diluted serum from study subjects and incubated at 37°C for 2 hours to allow IgG in serum to bind to the coated beads.
• a control was prepared by mixing coated beads with dilution buffer (PBS with 0.1% BSA). All samples were prepared in duplicate. After incubation, IgG-loaded beads were washed and mixed with 75 000 THP-1 cells/sample and incubated in a CO 2 -incubator at 37°C for 1.5-3 hours. After incubation samples were fixed in ice-cold 2% phosphate buffered formalin and the fluorescent uptake in THP-1 cells was monitored using an Accuri C6 flow cytometer.
• a phase I first in man, randomized double-blind study with single ascending doses of IdeS was conducted after approval from Swedish regulatory and ethical authorities. The objectives were to assess the safety, efficacy, pharmacokinetics, and immunogenicity of IdeS in healthy human subjects following intravenous administration.
• a total of 29 healthy subjects were included and divided into four dose groups.
• the subjects in each dose group were randomized and received either IdeS or placebo. Infusions were given intravenously over 30 minutes for the first two subjects in each group and over 15 minutes for the subsequent subjects.
• the starting dose was 0.01 mg/kg BW (N IdeS : 8 and N Placebo : 4) and after evaluation by the Data Monitoring Committee the dose was stepwise increased to 0.04 mg/kg BW (N IdeS : 4 and N Placebo : 2), 0.12 mg/kg BW (N IdeS : 4 and N Placebo : 1) and finally 0.24 mg/kg BW (N IdeS : 4 and N Placebo : 2).
• the subjects were monitored until day 64 after dosing with more intensive monitoring during the first week. All subjects were male Caucasians with a median age of 23 (range: 20-41) years, weight 76 (range: 59-100) kg with a BMI of 23 (range: 20-30) kg/m 2 and there were no statistical significant differences in demographics between the groups.
• nasopharyngitis was reported for ten out of twenty subjects on IdeS and for six out of nine subjects on placebo. Seven subjects reported headache at nine occasions (all on IdeS) whereas six subjects (five on IdeS and one on placebo) reported seven incidences of fatigue.
• IdeS concentrations in serum were measured by a LC-MS/MS method based on four peptides derived from Ides, and serum concentration versus time data were analysed by non-compartmental analysis, The pharmacokinetic parameters were calculated up to 24 hours post dosing, as the remaining concentrations were around or below the estimated quantitative range of the method.
• the serum concentration of IdeS could be described as a multi-phase elimination curve where the main fraction of the exposure was eliminated during the first 24 hours after dosing.
• the mean t1 ⁇ 2 was 4.1 ( ⁇ 2.6) hours at 0.12 mg/kg BW and 4.9 ( ⁇ 2.8) hours at 0.24 mg/kg BW.
• the C max was 5.0 ( ⁇ 2.5) mg/L at 0.12 mg/kg BW and 8.3 ( ⁇ 3.7) mg/L at 0.24 mg/kg BW ( Fig. 3 B) .
• IdeS cleaves IgG in two steps (Ryan et al., 2008; Vindebro et al., 2013).
• the first reaction is a very rapid and efficient cleavage of one of the two heavy chains generating a single cleaved IgG (scIgG), still having one of the two heavy chains intact.
• the scIgG is a less sensitive but still a functional substrate for IdeS, and this second cleavage generates F(ab') 2 and Fc fragments.
• IdeS had full or close to full effect within 6 hours in all 8 subjects dosed with 0.12 or 0.24 mg/kg BW, i.e. the IgG pool was converted into F(ab') 2 and Fc fragments ( Fig. 4 A and B) .
• the effect was remarkably rapid and the IgG pool was converted into scIgG already during dosing (14 min after starting administration, i.e. 1 min prior to full dose) and maximal effect was accomplished 2-6 hours after dosing in all subjects.
• Newly synthesized intact IgG was detectable in serum two weeks after dosing and after three weeks the level of intact IgG had further increased and constituted the main IgG fraction in serum. ( Fig. 4 C) .
• the dynamics of the Fab- and Fc-containing fragments in serum was analyzed using one Fab- and one Fc-specific ELISA method.
• the ELISAs did not completely distinguish between the different IgG specimens; i.e. F(ab') 2 , Fc, scIgG and intact IgG.
• the Fab-ELISA measured all Fab-containing IgG fragments; i.e. intact IgG, scIgG, and F(ab') 2
• the Fc-ELISA measured all Fc containing fragments; i.e. intact IgG, scIgG and free Fc.
• a majority of the Swedish population has IgG antibodies against the antigen components of the DTaP-IPV//PRP ⁇ T (Pentavac ® ) vaccine (diphtheria, tetanus, pertussis, polio and Haemophilus type b).
• the vaccine is part of the Swedish childhood vaccination schedule and most individuals have received repeated injections of this or of a similar vaccine. This was utilized in an exploratory study where pre-existing IgG against these antigens were measured. The results showed that the effect of IdeS on antigen-specific IgG showed the same pattern as on the total IgG in each individual. In addition, the reappearance of these antigen-specific IgG antibodies was similar to that of total IgG ( Fig. 7 ).
• IgG from serum samples collected pre-dose and at different time-points after IdeS dosing were captured on fluorescent beads, washed and mixed with effector cells and phagocytosis was measured as per cent of the effector cells with at least one phagocytized bead.
• beads without serum were used to monitor the spontaneous uptake of empty beads by effector cells.
• the phagocytosis assay showed that all subjects dosed with 0.24 mg/kg BW IdeS reached background phagocytic levels 24 hours after dosing ( Fig. 8 A ).
• IdeS being a bacterial protein and most humans have had previous contact with S. pyogenes
• all subjects had pre-formed anti-IdeS IgG antibodies and reacted as expected with an IgG response which peaked 2-3 weeks after the IdeS infusion.
• the amplitude of the anti-drug response varied substantially between individuals, although a dose-response pattern was noted.
• Six-twelve months after dosing all subjects were back to anti-IdeS antibody levels within the normal range (i.e. ⁇ 2-91 mg/L) and considering potentially neutralizing antibodies and the safety aspect it is anticipated that IdeS treatment could be repeated after 6-12 months.
• the IdeS specific CAP FEIA test developed in parallel with this clinical trial could be a valuable tool to guide clinicians when considering repeated dosing.
• the study also evaluated functional relevance of cleaving IgG with IdeS in a phagocytosis assay, where interaction with the Fc ⁇ -receptor is expected to play a major role.
• This assay showed that already a few hours post administration of IdeS, the phagocytic effect of remaining IgG/IgG-fragments was significantly reduced in all tested subjects, an effect that remained seven days later.
• the results show that IdeS has the capacity to inactivate Fc-mediated effector function in vivo in humans.
• IdeS alone and/or in combination with other B-cell attenuating drugs (e.g. Rituximab or Bortezumib) is a very attractive therapeutic approach for many conditions where IgG autoantibodies contribute to the pathology.
• B-cell attenuating drugs e.g. Rituximab or Bortezumib
• the immunogenic nature of IdeS most likely prevents chronic treatment although repeated treatment once or twice per year most likely will be possible.
• a judicious therapeutic approach utilizing the high efficacy of IdeS in combination with other drugs or technologies such as immune adsorption or plasma exchange, it should be possible to maintain low plasma levels of pathogenic antibodies for an extended timeframe.
• IdeS The removal of IgG by IdeS was temporary, suggesting that its best use may be for conditions with a monophasic course, such as antibody mediated graft rejection. This is currently being investigated in a phase II study with IdeS.
• Example 1 Transplantation in the presence of donor specific antibodies (DSA) risks resulting in a hyperacute antibody-mediated rejection with acute allograft loss.
• DSA donor specific antibodies
• the study in Example 1 demonstrates that IdeS is safe and well tolerated up to 0.24 mg/kg BW. At this dose IdeS completely cleaved the pool of plasma-IgG within 14 minutes after initiation of infusion. The level of intact IgG was reduced to less than 5% of its original level. The data clearly indicated that a single dose of IdeS is superior to both plasmapheresis and immunoadsorption with respect to efficiency and rate of plasma IgG reduction.
• IdeS treatment of sensitized kidney patients just prior to transplantation should rapidly and efficiently cleave IgG into F(ab') 2 - and Fc-fragments thereby reducing the serum levels of cytotoxic DSA to a level where living and deceased donor (LD and DD) transplantation is possible.
• the donor specific F(ab') 2 -fragments still in circulation at the time-point of transplantation may also prevent binding of e.g. low affinity IgM or residual IgG to the transplant thereby further protecting the organ from rejection.
• the objective of this study was to investigate if treatment with a clinically relevant dose of IdeS can turn a positive cross-match test into a negative using serum from sensitized patients and to investigate the correlation between the reduction in levels of total IgG and IgG specific to HLA class I and II.
• the investigated patients were diagnosed with stage 5 CKD and were on the waiting list for kidney transplantation.
• the patients were all sensitized and positive for anti-HLA.
• the patients were recruited by Prof. H. Ekberg at the Transplant Unit, Dept. of Nephrology and Transplantation, Sk ⁇ ne University Hospital in Malmö, Sweden and Prof. G. Tufveson at the Dept. of Transplant Surgery, Uppsala University Hospital, Uppsala, Sweden.
• the patients received written patient information and signed the informed consent before any study related procedures were started. Serum was isolated from 10 ml venous blood according to the hospitals procedure. To ensure confidentiality the principal investigator made the identity of the patients unavailable to the investigating scientists by assigning an identification number (PXX) to the serum samples.
• the samples were sent to the Clinical Immunology Division at the University Hospital in Uppsala for banking and a fraction of each serum was then sent to Hansa Medical AB in Lund for IdeS related analyses.
• the serum samples were sent to the Dept. of Clinical Chemistry at Sk ⁇ ne University Hospital in Lund, Sweden for determination of total IgG concentrations.
• Human serum samples treated with IdeS were analyzed for intact IgG using an ELISA assay developed by Hansa Medical AB. MaxiSorp 96-well ELISA plates were coated in carbonate buffer (pH 9.6) o/n at +4-8°C with 100 ng/well of AffiniPure F(ab') 2 fragment goat anti-human, F(ab') 2 fragment specific (Jackson #109-006-097). The plates were washed with PBS+Tween20 (0.05%) and blocked with PBS+2% BSA for one hour at RT.
• Calibrators and samples were diluted in PBS+0.1% BSA (dilution buffer). After washing the diluted calibrators (M-l, serum from healthy volunteer; conc. 11.2 g/l) and serum samples were added on the plate and left to incubate for one hour at RT. Plates were washed again and 50 ⁇ l biotin-SP-AffiniPure F(ab') 2 fragment goat anti-human IgG, Fc ⁇ fragment specific (Jackson #109-066-098) diluted 1:20 000, in dilution buffer, was added and incubated for 30 minutes.
• the ELISA assay for IdeS efficacy was conducted as in in Example 1, as was the CAP FEIA (ImmunoCap) assay for IdeS specific antibody responses. The results were used only for comparative purposes against the results reported in Example 1 and are not shown.
• the IdeS and placebo treated sera were analysed for anti-HLA IgG antibodies using SAB analyses against a panel of MHC class-I and -II antigens (LABScreen Single Antigen, One Lambda). The sera were also tested and scored for reactivity in a complement-dependent cytotoxicity (CDC) screen test on T and B cells from 23 donors. T-cells and B-cells were enriched using CD8 and MHC class-II magnetic beads (Dynal), respectively.
• the SAB and CDC analyses were conducted using validated methods in a clinical setting by Dr. Mats Bengtsson at the Clinical Immunology Division, Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, University Hospital, Uppsala, Sweden. The CDC reactions were scored according to the International Workshop procedure (Fuller et al., 1982).
• Splenocytes were prepared from Balb/c mice by Ficoll separation. Cells were washed in PBS (x2) and re-suspended to 2x10 6 cells/ml in DMEM:F12 (Difco) with 0.1% heat inactivated BSA. The serum samples were treated with DTT to inactivate IgM by mixing 45 ⁇ l serum with 5 ⁇ l 50 mM DTT and incubate for 30-45 minutes at 37°C. The CXM test was performed by adding 1 ⁇ l cell suspension (i.e. 2000 cells) and 1 ⁇ l of sample (i.e. serum or controls) to a 60-well Terasaki-plate (Nunc).
• Baby Rabbit Complement (5 ⁇ l) (Cedarlane) was added and the mix was further incubated for 60 minutes at RT.
• FluoroQuench AO/EB Stain Quench (5 ⁇ l) (One Lambda inc.) was added to each well and the mix was incubated for 15 minutes at RT. The cytotoxicity was scored (score 1-8) and documented with fluorescence microscopy.
• the graphs were constructed using GraphPad Prism version 5.0d for Mac OS X, GraphPad Software, San Diego California USA, www.graphpad.com.
• anti-IdeS levels were determined using IdeS-ImmunoCAP analysis and all 12 serum contained low levels (median: 4.5 mg/L; range ⁇ 2-14.8 mg/L) of anti-IdeS IgG (HMed Doc. No: 2012-041). There was no clear correlation between individual anti-IdeS levels or the levels of total IgG and IdeS efficacy. Five representative sera; i.e. P02, P04, P07, P08 and P09, were selected for further analyses of anti-HLA antibodies.
• Example 1 The pre-clinical studies described in Example 1 demonstrated that a single intravenous injection of IdeS in rabbits results in a rapid (within 1h) reduction of intact IgG down to 2-3% of the original level and that the IgG level remains low for several days after treatment. Similar results were obtained in the clinical phase I trial described in Example 1 after administering IdeS to healthy human subjects.
• the pool of plasma IgG was completely converted to scIgG already during administration of 0.24 mg/kg BW of IdeS (14 minutes after initiation of infusion) and two hours after dosing to pool IgG had been further converted to F(ab') 2 and Fc.
• the data showed that levels corresponding to ⁇ 5% of the original levels, most of which consisted of scIgG, could be reached already between 2-6 hours after dosing and that it took several days before the level started to gradually increase.
• IdeS and placebo treated serum from patients P02, P04, P07, P08 and P09 were subjected to a sera-sceen CDC test against a panel of T-cells (i.e. cells enriched for CD8+) and B cells (i.e. cells enriched for MHC class-II+) from selected and well-characterized donors.
• T-cells i.e. cells enriched for CD8+
• B cells i.e. cells enriched for MHC class-II+
• IdeS treatment could completely desensitize patients P02, P04, P07 and P09 and significantly improve the grade of sensitization for patient P08 (table 2.2).
• IdeS treatment improved the grade of sensitization for all patients (table 2.3). It could be concluded that IdeS-treatment clearly reduced the CDC reactivity against potential donors thereby increasing the chance of finding a suitable donor for all tested patients. It was also clear from the data presented here that IdeS-treatment had the capacity to turn a positive pre-transplantation cross-match into a negative thereby making a sensitized patient transplantable.
• a threshold at an MFI (raw) >1000 (sometimes >2000) is quite often used as a cut-off for a significant reactivity against a specific HLA antigen when considering transplantation of a sensitized patient.
• IdeS treatment could clearly reduce the number of HLA-antigens above these thresholds in all tested patients both at MHC class I and class II (table 2.4 and 2.5; Appendix I - II).
• IdeS treatment has the capacity to turn a positive CXM negative
• Naturally occurring antibodies against [Gal ⁇ -1,3-Gal] structures are the primary effectors of human hyperacute rejection (HAR) of nonhuman tissue. Unlike most mammals, humans lack a functional ⁇ -1,3-galactosyltransferase (GalT) gene and produce abundant anti-Gal antibodies, putatively in response to GalT+ enteric bacteria (Ding et al., 2008 and Pierson 2009). The objective was to investigate if the primate v.s. non-primate anti-Gal reactivity can be exploited as a pseudo marker to analyse the effect of IdeS using clinical serum samples from the phase I study of Example 1.
• HAR human hyperacute rejection
• the level of IgG was measured in consecutive serum samples collected before and after dosing of 0.24 mg/kg IdeS to human healthy subjects using a validated PD-ELISA (table 2.6). The data demonstrated that there was approximately a 10-fold decrease in IgG two hours after dosing and a 20-fold decrease 24 hours after dosing of IdeS.
• the PD-ELISA does not discriminate between intact fully functional IgG and scIgG with an attenuated Fc-effector function.
• SDS-PAGE analyses indicated that scIgG constituted the dominating fraction of the remaining IgG in these sera suggesting that the level of fully functional IgG is low already minutes after IdeS treatment (see Example 1). Table 2.2.
• Sera-screen test of sera from sensitized patients (P02, P04, P07, P08 and P09) treated with IdeS or placebo (PBS) against T cells from a panel of donors (N 23). Reactivity was scored by assigning a number 1-8 where 1 corresponds to 0% cytotoxicity and 8 corresponds to >80% cytotoxicity.
• Sera-screen test of sera from sensitized patients (P02, P04, P07, P08 and P09) treated with IdeS or placebo (PBS) against B cells from a panel of donors (N 23). Reactivity was scored by assigning a number 1-8 where 1 corresponds to 0% cytotoxicity and 8 corresponds to >80% cytotoxicity.
• HLA-DP HLA-DQ HLA-DR +PBS +IdeS +PBS +IdeS +PBS +IdeS P02 >1000 8 0 19 0 23 2 >2000 7 0 14 0 23 0 P04 >1000 0 0 7 0 16 2 >2000 0 0 7 0 11 0 P07 >1000 0 0 0 0 13 0 >2000 0 0 0 0 12 0 P08 >1000 7 0 27 23 33 23 >2000 1 0 27 16 33 2 P09 >1000 0 0 22 7 23 0 >2000 0 0 16 3 20 0 Table 2.6.
• IgG levels of IgG measured in serum samples from healthy subjects dose with placebo (503) or IdeS (504-506) using a validated PD-ELISA that measures intact IgG (plus scIgG).
• IgG Pre-dose 2h 24h 503 10.6 14.1 12.6 504 12.8 1.6 0.53 505 8.9 0.91 0.62 506 9.5 0.81 0.65
• mouse spleen cells were stained for FACS analyses with undiluted consecutive serum samples collected before and at different time-point after dosing of 0.24 mg/kg IdeS in human healthy subjects.
• the binding of IgG to the cells was detected using a hFc ⁇ -specific reagent.
• the data demonstrated a clear shift 24 hours after IdeS treatment that was sustained up to 96 hours after treatment (representative graph in figure 16 ) consistent with the demonstrated reduction in total IgG.
• the cleavage products i.e.
• F(ab') 2 - and Fc ⁇ -fragments have a rapid elimination from circulation and reaches low plateau levels 1-2 days after IdeS treatment (see Example 1). Consequently, competition between potentially remaining intact IgG and F(ab') 2 -fragments for binding to target antigens was expected to be insignificant in this assay. It was concluded that the pre-dose samples collected in the phase I trial contain IgG that bind mouse cells and that IdeS treatment reduced this reactivity.
• Consecutive serum samples collected before dosing, two hours after dosing and 24 hours after dosing from three healthy subjects (504, 505 and 506) dosed with 0.24 mg/kg BW were tested in a CDC-CXM against spleen cells from Balb/c mouse. All pre-dose samples reacted strongly (score 8) whereas the samples collected at 2 and 24 hours after IdeS treatment were completely negative (score 1) (table 2.7 and figure 17 ). Table 2.7. Xenogenic cross-match test with sera from healthy subjects (504-506) dosed with 0.24 mg / kg IdeS and spleen cells from Balb / c mouse. Reactivity was scored by assigning a number 1-8, where 1 corresponds to no cytotoxicity and 8 corresponds maximum cytotoxicity. Pre-dose 2h 24h 504 8 1 1 505 8 1 1 506 8 1 1
• IdeS-treatment can reduce the serum level of specific IgG with the ability to bind murine cell-surface targets and that this effect is sustained for several days after IdeS-treatment.
• the fact that the IgG did not recover already within the first day(s) following IdeS treatment clearly indicated that IdeS not only cleaved plasma IgG but also IgG located outside the vascular system, i.e. in the interstitial fluid.
• serum collected two and 24 hours after IdeS-treatment from subjects treated with 0.24 mg/kg IdeS could not mediate complement-dependent cytotoxicity (CDC) against mouse target cells, clearly demonstrating that IdeS can turn a positive CMX result into a negative result.
• CDC complement-dependent cytotoxicity
• Serum from patient P02 demonstrated CDC-reactivity against T-cells from 4 donors and IdeS treatment could completely neutralize this reactivity (score: 1)(table 2.2).
• the pre-treatment serum reacted against 16 out of the 23 B-cell donors and after treatment (reduced) reactivity remained against only two donors (table 2.3) whereas the remaining were negative (score: 1).
• the SAB analyses demonstrated that before IdeS treatment the patient serum had reactivity (i.e. MFI>1000) against HLA-A, -B and -C antigens as well as HLA-DP, -DQ and -DR antigens (tables 2.4 and 2.5; figure 11 ).
• IdeS treatment reduced the reactivity against all antigens and very few (i.e. two HLA-DR antigens) had reactivity above MFI: 1000 (non were above MFI: 2000)(table 2.4 and 2.5; figure 11 ).
• the overall conclusion is that IdeS can close to completely desensitize serum from patient P02.
• the two donors (PC:20 and PC:21) where IdeS treatment had full effect in the T cell CDC but no effect in the B-cell CDC carries the following HLA-DR alleles; PC:20 - DRB1*11:01, DBR3*02:02 and PC:21 - DRB1*01:01, DBR1*16:01:01, DRB5*0202. All of these antigens are present on the SAB array.
• the serum from patient P07 reacts with intermediate reactivity against DRB1*11:01 (MFI: 4552) and weakly against DBR3*02:02 (MFI: 1203) but after IdeS treatment the signal is below 100 for both antigens.
• the serum has no reactivity against DRB1*01:01 DRB1*16:01:01 or DRB5*0202 neither before nor after IdeS treatment.
• the conclusion is that IgG against the MHC class II antigens cannot explain the lack of effect in the B-cell CDC using these donors and it is believed to speculate that IgM could be involved.
• the overall conclusion is that IdeS is highly effective in reducing the levels of anti-HLA antibodies in serum from patient P07.
• the serum from patient P08 is highly reactive against all tested donors in the T and B cell CDC tests (table 2.2 and 2.3).
• T-cell test there are 14 donors where IdeS can completely neutralize the reactivity and 6 donors where IdeS has no measurable effect.
• B cell test there are 5 donors where IdeS can completely neutralize the reactivity and since IdeS also have full activity in the T-cell test using the same donors it is plausible to attribute this reactivity to being merely MHC class I reactivity.
• PC:14, PC:16 and PC:20 there are also 3 donors (PC:14, PC:16 and PC:20) where IdeS has full effect in the T cell test and no measurable effect in the B cell test.
• the serum Before IdeS treatment the serum has the broadest reactivity among the tested sera (tables 2.4 and 2.5; figure 14 ).
• the serum from patient P09 had strong CDC-reactivity (i.e. CDC-score: 8) against T cells from 7 donors and IdeS treatment could completely neutralize this reactivity (table 2.2).
• the SAB analyses demonstrated that before IdeS treatment the patient serum had reactivity (i.e. MFI>1000) mainly against HLA-A-antigens as well as HLA-DQ and -DR antigens (tables 2.4 and 2.5; figure 15 ).
• IdeS reduced the reactivity against all antigens and only a few HLA-DQ antigens had reactivity above MFI: 1000 after treatment.
• the overall conclusion is that IdeS can close to completely desensitize serum from patient P09.
• IdeS Treatment of sera from sensitized patients suffering from stage 5 CKD using a clinically relevant dose of IdeS could rapidly and substantially reduce the level of total-IgG. Furthermore, this activity was directly reflected in a reduction in the levels of specific and/or broad-reactive anti-HLA IgG in serum from these patients. SAB analyses clearly demonstrated that IdeS treatment reduced the level of IgG-antibodies to all MHC-antigens tested positive in serum from all analyzed patients. In the majority of cases the reactivity to individual MHC-antigens after IdeS treatment was below the critical MFI, i.e. below 1000.
• IdeS could reduce the reactivity in all tested patient serum samples and had the capacity to turn a positive cross-match into a negative. Furthermore, serum collected from healthy subjects before treatment with 0.24 mg/kg IdeS reacted strongly in CDC-CXM against mouse target cells, whereas serum collected two and 24 hours after IdeS-treatment were negative, which further proves that IdeS-treatment has the capacity turn a positive CXM negative. Taken together the data presented here clearly show that IdeS treatment just prior to transplantation has the potential to desensitize a highly sensitized patient, thereby allowing transplantation and avoiding an acute antibody mediated rejection.
• Example 2 Appendix I - MFI Raw data - MHC class-I antigens
• Example 2 Appendix II - MFI Raw data - MHC class-II antigens
• IdeS rapidly cleaves all plasma IgG after intraqvenous administration to human subjects.
• the following in vitro and ex vivo data show that IdeS not only cleaves soluble IgG as previously shown, but also cuts off the F(ab') 2 part of the B-cell receptor complex from surface IgG-positive B-cells.
• the truncation of the BCR through IdeS has strong inhibiting effects on the induction of secreted IgG from R848 and IL-2 activated CD27 positive memory B-cells, while the IgM secretion of surface IgM-positive BCR cells are not reduced by the treatment with IdeS.
• a sensitive colorimetric assay (CCK-8) was used to measure cell viability.
• Cells were treated with PBS or 30 ⁇ g/ml IdeS and 2 x 10 4 cells/well were seeded in 96-well plates and cultured for 24 hours.
• CCK-8 (CCK-8 cell counting kit 8, Dojindo Laboratories, Japan) was added and the absorbance at 450 nm was followed at different time points.
• Nu-DUL-1 cells they were treated with PBS or 30 ⁇ g/ml IdeS and different amount of cells were seeded in 96-well plates and cultured for 24 hours prior to addition of CCK-8.
• peripheral blood was collected in heparin tubes supplemented with IdeS at 30 ⁇ g/ml or PBS and incubated at 37°C, 5% CO 2 for 30 minutes.
• 250 ⁇ l RosetteSep ® Human B cell Enrichment cocktail (#07905, StemCell Technologies) was added to 5 ml blood, mixed well and incubate for 20 minutes at room temperature.
• Samples were diluted with an equal volume of PBS supplemented with 2% FCS prior to density gradient separation (Ficoll-PaquePLUS).
• Harvested B-cells were counted and adjusted to 20 x 10 4 cells/ml in RPMI1640 supplemented with 10% FCS and PEST. 2 x 10 4 cells/well were seeded in triplicates in 96-well plates and cultured for 24 hours prior to addition of CCK-8.
• Plasma collected during density gradient separation of heparin blood treated with PBS or different amounts of IdeS was used to verify IdeS efficacy on soluble IgG.
• the SDS-PAGE analyses were performed according to the manufacturer's instructions (Bio-Rad Laboratories, CA, USA). Briefly, 1 ⁇ l of plasma was separated on 4-20% Mini-PROTEAN ® TGX TM precast gels (Bio-Rad) at 200 V for 40 minutes under non-reduced conditions. The gels were stained with GelCode Blue stain reagent (Pierce, Thermo Fisher Scientific, MA, USA) according to the manufacturer's instructions and the gels were scanned.
• Nu-DUL-1 cells were treated with PBS or different amounts of IdeS for one hour at 37°C prior to extensive washing in order to remove any remaining IdeS.
• the cells were seeded in 96-well plates in RPMI1640 supplemented with 10% FCS and PEST. One plate was immediately used for flow cytometry analysis of intact IgG and the other was cultured (37°C, 5% CO 2 ) for 24 hours prior to analysis.
• Cells were stained with a biotinylated antibody specific for the F(ab') 2 part (#109-066-097, Jackson) followed by Streptavidin-APC (#016-130-084, Jackson) and cells were monitored in FL4 using an Accuri C6 flow cytometer.
• Peripheral blood was collected in heparin tubes (BD Vacutainer, #367876) from healthy volunteers and treated with either 30 ⁇ g/ml IdeS or PBS for one hour at 37°C prior to isolating PBMC using density gradient separation (Ficoll-PaquePLUS).
• the PBMC interface was collected, washed in PBS and re-suspended in culture medium (RPMI1640 supplemented with 10% FCS and PEST).
• PBMCs were counted, adjusted to 2 x 10 6 cells/ml and a sample was removed, fixed in PFA, washed in PBS supplemented with 0.1% BSA and stored at 4°C until flow cytometry analysis.
• the remaining cells were cultured and samples were removed and PFA fixed at indicated time points.
• biotinylated anti-CH1-IgG #710.3202.100, BAC
• Fc-part of IgG goat anti-human Fc-specific F(ab') 2 fragment #109-066-098, Jackson
• Cells were further double stained with PE-conjugated anti-CD19 (#IP-305-T100, ExBio) and Streptavidin-APC (#016-130-084, Jackson).
• the lymphocyte population was gated using forward-side scatter and double positive cells were monitored in FL2 and FL4 using an Accuri C6 flow cytometer.
• Nu-DUL-1 cells were cultured overnight in serum free medium in order to minimize background phosphorylation prior to start of signalling experiments. The next day PBS or 30 ⁇ g/ml IdeS was added and the cells were cultured (37°C, 5% CO 2 ) for 30 min. 1 x 10 6 cells were removed and fixed for 5 min in PFA followed by 10 min permeabilization in 70% ethanol on ice. Cells were washed in PBS supplemented with 0.1% BSA and stored at 4°C until analysis (zero sample).
• the BCR of the remaining cells was cross-linked by addition of 10 ⁇ g/ml goat anti-human F(ab') 2 specific F(ab') 2 (Jackson #109-006-097) and cell-samples were collected at different time points, fixed and permeabilized.
• the fixed cells were stained for flow cytometry analysis using APC-conjugated phospho-specific ERK1/2 (#17-9109-42, eBioscience) and PE-conjugated phospho-specific PLC- ⁇ 2 (#558490, BD). Cells were monitored in FL2 and FL4 using an Accuri cytometer C6.
• Peripheral blood was collected in heparin tubes (BD Vacutainer, #367876) from healthy volunteers and PBMC were isolated using density gradient separation (Ficoll-PaquePLUS).
• the PBMC interface was collected, washed in PBS and re-suspended in culture medium (RPMI1640 supplemented with 10% FCS and PEST).
• PBMCs were adjusted to 2 x 10 6 cells/ml and seeded either with IdeS (final concentration 0.3, 3 and 30 ⁇ g/ml) or PBS.
• Cells were stimulated with a mixture of R848 and rIL-2 according to the manufacturer's recommendation (MabTech) and cultured for 72-96 hours.
• Cells intended for the short time treatments were left in tubes supplemented with PBS or IdeS and incubated for one hour at 37°C prior to washing 3 x 12 ml with PBS and 1 x 12 ml in culture medium. These cells were seeded and treated with R848/rIL-2 as above.
• ELISpot filter plates were pre-wetted with 70% ethanol, washed with sterile water and incubated at 4°C overnight with capture antibody (ELISpotPLUS Mabtech kit #3850-2HW-Plus for monitoring IgG producing cells, ELISpotPLUS Mabtech kit #3845-2HW-Plus for monitoring IgM producing cells and ELISpotBASIC Mabtech kit #3860-2H for monitoring IgA producing cells).
• the ELISpot filter plates were wash and blocked for at least 30 min with culture medium prior to seeding cells.
• ELISpot-plates were washed and biotinylated detection antibodies for total IgG, IgM and IgA analysis (included in the named kits) were incubated for two hours at room temperature. Plates were wash and incubated for one hour at room temperature with Streptavidin-HRP before they were washed and incubated with TMB ready-to-use solution and developed until distinct spots emerged. The plates were washed in tap water and allowed to dry in the dark. The filters were photo documented and spots were manually counted.
• peripheral blood was collected in heparin tubes supplemented with IdeS at 30 ⁇ g/ml or PBS and incubated at 37°C, 5% CO 2 for 30 minutes.
• 250 ⁇ l RosetteSep ® Human B cell Enrichment cocktail (#07905, StemCell Technologies) was added to 5 ml blood, mixed well and incubate for 20 minutes at room temperature. Samples were diluted with an equal volume of PBS supplemented with 2% FCS prior to density gradient separation (Ficoll-PaquePLUS).
• IdeS cleaves the IgG-type of BCR in a first in man clinical study
• Cells were washed and stored in PBS supplemented with 0.5% BSA until all time points were collected. Cells were stained with 10 ⁇ g/ml biotinylated anti-CH1-IgG (#710.3202.100, BAC) for detection of the F(ab') 2 part of IgG. For detection of the Fc-part of IgG 0.5 ⁇ g/ml goat anti-human Fc-specific F(ab') 2 fragment (#109-066-098, Jackson) was used. Cells were further double stained with PE-conjugated anti-CD19 (#21270194, Immunotools) and Streptavidin-APC (#016-130-084, Jackson).
• the lymphocyte population was gated in the pre-dose sample for each individual and this gate was then used for all time points for a subject.
• CD19 + cells were monitored in FL2 and the F(ab') 2 /Fc-signal was monitored in FL4.
• CD19 + cells were monitored in M1 (FL2) and these cells were further monitored for presence of a signal upon anti-Fc and anti-Fab staining (FL4).
• FL2 the F(ab') 2 /Fc-signal
• FL4 CD19 + cells were monitored in M1 (FL2) and these cells were further monitored for presence of a signal upon anti-Fc and anti-Fab staining (FL4).
• UR upper right
• MFI mean fluorescent intensity
• the frequency of double positive cells was calculated using the following formula: MFI in UR x cell counts in UR cell counts in M 1 This formula was used to be able to appreciate the difference in MFI when only low cell counts were present in UR.
• IdeS cleaves the IgG-type of BCR with similar efficacy as soluble IgG
• a Fab-fragment specific F(ab') 2 antibody was used to detect the presence of the Fab-part of BCR since the antibody cross-reacts with the light-chain present in both IgG and IgM.
• antibodies directed at the Fc-part of IgG was used. Intact membrane-bound IgG could not be detected on the cell surface at an IdeS concentrations above 4 ⁇ g/ml.
• Daudi cells having an IgM-type of BCR were not affected even at high concentrations of IdeS ( Fig. 20A ).
• Nu-DUL-1 cells were treated with different concentrations of IdeS and incubated at 37°C for 30 min prior to FACS staining. IdeS was shown to efficiently remove the F(ab') 2 part of IgG present in the BCR leaving the cleaved Fc-part attached to the membrane ( Fig. 20B ).
• CD19 + B-cells only constitute a few per cent of the total PBMC population.
• CD19 + B-cells were enriched using negative selection (RosetteSep), which generated >90% CD19 + cells ( Fig. 22A ).
• Approximately 10% of this population stained double positive for surface IgG and CD27 prior to IdeS treatment ( Fig. 22B ).
• IdeS treatment less than 1% of the CD19 + /CD27 + cells stained positive for cell surface IgG ( Fig. 22B ).
• these data show for the first time that the BCR on class-switched memory B cells i.e. CD19 + /CD27 + /surface IgG + cells is efficiently cleaved by IdeS.
• the Nu-DUL-1 cells were treated with different concentrations of IdeS, washed to remove IdeS and cultured. Fractions of cells were removed one and 24 hours after treatment and analysed for membrane bound IgG by flow cytometry. One hour after treatment there was no detectable IgG at IdeS concentrations > 4 ⁇ g/ml but 24 hours after treatment, the Fab specific signal was back at the original levels demonstrating that the membrane bound IgG had recovered ( Fig. 23A ).
• Nu-DUL-1 cells were also analysed for proliferative capacity using BrdU incorporation and there was no difference in proliferation after cleaving the IgG-type of BCR even when IdeS treatment was continued over 24 hours ( Fig. 23B ).
• Substances with known anti-proliferative capacity (puromycin and cytochalasin D) had a strong anti-proliferative effect on the cells.
• the viability of Nu-DUL-1 cells was also investigated by treating cells with a high dose of IdeS (30 ⁇ g/ml) for 24 hours and viability was analysed using the CCK-8 assay and there was no effect on cell viability after IdeS treatment ( Fig. 23C ).
• a fraction of cells were removed at different time points, fixed and stained with anti-CD19 for B-cell linage and further stained with anti-Fab or anti-Fc to monitor IgG-BCR.
• the IgG-type of BCR was rapidly regenerated also on normal human CD19 + cells and already within 16 hours after cleavage the number of anti-Fab positive cells was back to pre-treatment levels though still not reaching the full MFI. This indicates that 16 hours post IdeS treatment of PBMCs the cells again have intact IgG-BCR on the surface even though all IgG-BCR are not yet replaced ( Fig. 24A ).
• the anti-Fc signal was not affected by the treatment demonstrating that IdeS treatment shed the F(ab') 2 from the IgG-type of BCR ( Fig. 24B ). Because B-cells only account for a few per cent of the total PBMC population we also used a B-cell enrichment kit (RosetteSep), which generated >90% CD19 + cells. Approximately 20% of the CD19 enriched cell population stained positive for IgG using both the F(ab') 2 and the Fc specific reagents ( Fig. 25 ). The cell surface recovery experiment was repeated using these purified cells and IdeS treatment efficiently removed the F(ab') 2 part of the membrane bound IgG leaving the Fc-part intact ( Fig. 25A and 25B ).
• IdeS treatment inhibits BCR signalling
• BCR signalling is important in the activation, survival, and differentiation of B lymphocytes.
• the initial event after BCR engagement is the activation of Lyn and Syk, which is then further propagated into activation of PLC- ⁇ 2 and ERK1/2.
• the described experiments clearly showed that IdeS could cleave the IgG-type of BCR, which should have implications on the BCR signalling.
• PLC- ⁇ 2 and ERK1/2 phosphorylation were monitored as downstream indicators for the BCR signalling cascade.
• the BCR on Nu-DUL-1 cells was cross-linked using a F(ab') 2 specific antibody it was shown that the cells were unable to signal through the BCR after IdeS treatment ( Fig. 27A and 27B ).
• IdeS blocks B-cell maturation
• IdeS does not affect the viability of cell lines or primary B-cells but renders them unable to respond to antigen.
• PBMCs were collected, treated with IdeS and stimulated with recombinant IL2 and R848 in order to activate memory B-cells and differentiate them into Ig-producing cells (Jahnmatz et al., 2013). After 72-96 hours the cells were extensively washed in order to remove IdeS and analysed for frequency of Ig-producing cells. IdeS was also added on day three of IL2/R848 culture as additional control.
• IdeS cleaves the IgG-type of BCR in vivo in humans
• IdeS has recently been tested in a first in man study where healthy human subjects were given single ascending i.v. doses (ClinicalTrials.gov Identifier: NCT01802697) (submitted manuscript). The highest tested dose given to four subjects was 0.24 mg/kg BW.
• An exploratory part of the trial was to analyse the integrity of the IgG-type of BCR on circulating CD19 + lymphocytes at different time-points after IdeS administration. Peripheral blood was collected and PBMCs were purified at pre-dose, 2 h, 24 h, 48 h and 96 h post administration. Cells were immediately fixed to prevent further cell metabolism and stored until all time-points from a subject could be analysed.
• the PBMCs were double-stained for CD19 and F(ab') 2 respectively Fc-fragments and analysed using flow cytometry.
• the method can measure the frequency and mean fluorescence intensity of cells having F(ab') 2 (i.e. intact IgG-type of BCR) and Fc on their cell-surface. However, the method does not discriminate between intact and single-cleaved BCR.
• the results demonstrated that the number of CD19 + cells that stained positive for F(ab') 2 was reduced already 2 h after treatment with IdeS (0.24 mg/kg BW IdeS) while the number of cells that stained positive for Fc was not reduced ( Fig. 29 ).
• B-cells are very potent antigen-presenting cells (Lanzavecchia 1990, Avalos & Plough 2015) and can with high efficiency present an antigen on HLA after specific BCR-mediated endocytosis, therefore the loss of the antigen-binding fragment of the BCR upon IdeS cleavage is likely to have an impact on antigen presentation to CD4 + T-cells.
• IdeS is currently developed for desensitisation of highly sensitized patients on the waiting list for kidney transplantation. These patients have developed antibodies against most donors and there is little chance of finding a matching donor. By removing donor specific antibodies (DSA) using IdeS prior to transplantation patients can be made eligible for transplantation despite a positive cross-match before treatment. An additional effect of IdeS treatment is the instant generation of free F(ab') 2 fragments from DSA with retained binding capacity.
• F(ab') 2 fragments may bind and block epitopes in the graft and since the F(ab') 2 fragments have lost their Fc-mediated functions such as complement fixation (CDC), antibody dependant cellular cytotoxicity (ADCC) and antibody dependant cellular phagocytosis (ADCP) the F(ab') 2 fragments may have the capacity to block out IgM and newly formed IgG DSA and thereby provide an additional protection of the graft.
• CDC complement fixation
• ADCC antibody dependant cellular cytotoxicity
• ADCP antibody dependant cellular phagocytosis
• DSA-specific memory B-cells are initially not capable of responding to donor antigens. This may potentially have long term effects on the outcome of graft survival as the initial activation of memory B-cells and generation of long-lived plasma cells is likely to be affected by IdeS treatment.
• CCK-8 reagent from CCK-8 cell counting kit; Dojindo Laboratories, Japan was added and continued incubation for 1 hour prior to reading the plate at 450 nm in an ELISA-plate reader (spectrophotometer).
• the CCK-8 assay allows sensitive colorimetric assays for the determination of cell viability in cell proliferation and cytotoxicity assays.
• the anti-Fab agent used was F(ab') 2 specific goat F(ab') 2 fragment (Jackson #109-006-097, 1.3 mg/ml).
• the anti-Fc agent used was Fc specific goat F(ab') 2 fragment (Jackson #109-006-098, 1.3 mg/ml).
• the control was mouse gamma globulin (Jackson #015-000-002, 11.4 mg/ml). The control was selected to be from the same manufacturer as the tested anti-Fab and anti-Fc and because mouse IgG is not cleaved by IdeS.
• Therapeutic intervention can be accomplished by means of an antibody targeting an epitope which is created in the BCR as a consequence of IdeS cleavage or even by targeting a common epitope on the Fc (as shown here).
• the therapeutic antibody is preferably one that is not cleaved by IdeS and has high degree of Fc-effector functions i.e. CDC, ADCC and ADCP.
• the antibody could also be coupled to a cytotoxic agent i.e. radioisotope or toxin.
• Another possibility is provided by the considerably quicker recovery of intact IgG on membrane bound BCR compared to recovery of IgG in circulation. This makes it possible to use the F(ab') 2 part as target and not only the Fc-part.
• Recovery of the IgG-BCR on memory B-cells opens up the possibility to use antigens (linked to toxins or radioisotopes) to specifically target memory B-cells with particular non-desired specificities (i.e. anti-HLA or anti-insulin).

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Genetics & Genomics (AREA)
• Zoology (AREA)
• Wood Science & Technology (AREA)
• Immunology (AREA)
• Biochemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Molecular Biology (AREA)
• Biomedical Technology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Microbiology (AREA)
• Biotechnology (AREA)
• General Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Gastroenterology & Hepatology (AREA)
• Biophysics (AREA)
• Cell Biology (AREA)
• Urology & Nephrology (AREA)
• Hematology (AREA)
• Mycology (AREA)
• Virology (AREA)
• Developmental Biology & Embryology (AREA)
• Transplantation (AREA)
• Oncology (AREA)
• Pathology (AREA)
• General Physics & Mathematics (AREA)
• Analytical Chemistry (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (2)

Family

ID=51587261

Family Applications (2)

Family Applications After (1)

Country Status (26)

Families Citing this family (29)

Citations (1)

Family Cites Families (14)

• 2014
  • 2014-07-25 GB GBGB1413240.1A patent/GB201413240D0/en not_active Ceased
• 2015
  • 2015-07-10 HR HRP20251560TT patent/HRP20251560T1/hr unknown
  • 2015-07-10 KR KR1020177005456A patent/KR102565244B1/ko active Active
  • 2015-07-10 CN CN201580049441.3A patent/CN106714834A/zh active Pending
  • 2015-07-10 DK DK15756845.2T patent/DK3171891T3/da active
  • 2015-07-10 BR BR112017001420A patent/BR112017001420A2/pt not_active Application Discontinuation
  • 2015-07-10 US US15/328,879 patent/US10973889B2/en active Active
  • 2015-07-10 CA CA2955704A patent/CA2955704A1/en active Pending
  • 2015-07-10 EP EP15756845.2A patent/EP3171891B1/en active Active
  • 2015-07-10 MY MYPI2017000280A patent/MY196858A/en unknown
  • 2015-07-10 EP EP25199052.9A patent/EP4663755A2/en active Pending
  • 2015-07-10 CN CN202210234712.4A patent/CN114949187A/zh active Pending
  • 2015-07-10 AU AU2015294125A patent/AU2015294125B2/en active Active
  • 2015-07-10 MX MX2017001138A patent/MX2017001138A/es unknown
  • 2015-07-10 PL PL15756845.2T patent/PL3171891T3/pl unknown
  • 2015-07-10 JP JP2017524097A patent/JP6708641B2/ja active Active
  • 2015-07-10 EA EA201790192A patent/EA039169B1/ru unknown
  • 2015-07-10 KR KR1020237026683A patent/KR20230119267A/ko not_active Ceased
  • 2015-07-10 PT PT157568452T patent/PT3171891T/pt unknown
  • 2015-07-10 WO PCT/EP2015/065895 patent/WO2016012285A2/en not_active Ceased
  • 2015-07-10 ES ES15756845T patent/ES3054696T3/es active Active
  • 2015-07-10 LT LTEPPCT/EP2015/065895T patent/LT3171891T/lt unknown
  • 2015-07-10 RS RS20251260A patent/RS67520B1/sr unknown
  • 2015-07-10 IL IL249981A patent/IL249981B/en unknown
  • 2015-07-10 SI SI201532086T patent/SI3171891T1/sl unknown
  • 2015-07-10 FI FIEP15756845.2T patent/FI3171891T3/fi active
  • 2015-07-10 SG SG11201700172WA patent/SG11201700172WA/en unknown
• 2017
  • 2017-01-24 CO CONC2017/0000571A patent/CO2017000571A2/es unknown
  • 2017-01-25 CL CL2017000191A patent/CL2017000191A1/es unknown
• 2021
  • 2021-03-03 US US17/191,634 patent/US12397044B2/en active Active
• 2025
  • 2025-07-07 US US19/261,759 patent/US20260000739A1/en active Pending

Patent Citations (1)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events